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Chalmers University of Technology 
 
Liposomes are attractive vaccine carriers due to their potential to act as adjuvants, and to 
the fact that their composition and characteristics are virtually endlessly customizable. 
However, the precise physicochemical profile of an ideal carrier liposome for mucosal 
vaccines is still widely unknown, and how different properties affect key steps in the 
acquisition of protective immunity remains to be elucidated. Additionally, there is no 
consensus in the field regarding characterization of vaccine formulations, often with 
incomplete reporting of properties as a result. The focus of this work is therefore twofold: 
i) to contribute to a better understanding of how the physicochemical profile of vaccine 
carrier liposomes impacts the development of protective immunity using models at 
different levels of complexity, and ii) to improve and simplify the physicochemical 
characterization of liposomes through development and use of new analytical methods. 
The work in the first area consists of, firstly, an in vivo characterization of the biological 
response to vaccine liposomes carrying a vaccine protein and characterized by varying 
surface hydrophilicity (PEGylation). This study showed that non-PEGylated vaccine 
liposomes more efficiently induced local cell- and antibody-mediated immune responses, 
as well as better protection against a lethal virus challenge than both PEGylated liposomes 
and free vaccine protein. Secondly, in vitro studies focused on how liposome stiffness 
influences dendritic cells, investigating effects on uptake, antigen presentation and cellular 
activation. These investigations demonstrated that stiff, gel phase liposomes were able to 
more efficiently activate dendritic cells and induce significantly higher levels of antigen 
presentation and co-stimulatory signaling compared to both soft, fluid phase liposomes, 
and free vaccine protein. The work in the second part comprises two studies: a surface 
plasmon resonance-based method to characterize the influence on liposome deformation 
from specific multivalent interactions with supported cell membrane mimics, and a 
waveguide microscopy technique for characterization of optical properties of individual 
liposomes. While the latter method might become valuable in the context of quantifying 
the efficiency of dye labelling of liposomes, the surface plasmon resonance study offered 
information on how liposome deformation depends on membrane stiffness and ligand-
receptor pair density. Taken together, the work presented in this thesis demonstrate the 
value of multidisciplinary approaches to complex biological and medical challenges. 
 
Keywords: liposomes, nanoparticles, vaccine carriers, influenza, dendritic cells, antigen 
presentation, cellular uptake, flow cytometry, fluorescence microscopy, surface plasmon 
resonance 
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1  	  
Introduction 
The origin of modern vaccinology is often cited as being Edward Jenner’s trials with 
conferring protection against smallpox through controlled infection with the related, 
though relatively harmless, cowpox virus in the late 18th century.[1] Although inoculation 
was practiced already long before then, his work marked the beginning of the systematic 
efforts that lead to the global eradication of smallpox in 1979, in what is arguably one of 
the biggest achievements of modern medicine.[2] Over these centuries, vaccine technology 
has developed from the early inoculations, using material from lesions of infected persons; 
via industrially produced vaccines containing whole pathogens, either attenuated or 
inactivated, to the use of subunit vaccines containing only well-defined, carefully chosen 
components of the infectious agent. This development, enabled by the pursuit of 
understanding the transmission of disease as well as our natural defense against it, the 
immune system, has led to safer and more effective vaccines. Even so, we are still faced 
with challenges; the overwhelming majority of diseases have not yet been eradicated, but 
continue to exist and evolve. Indeed, diseases caused by rapidly mutating pathogens, such 
as influenza, remain a considerable challenge since vaccine formulations constantly need 
to be adapted to address the specific strain(s) in circulation at a certain point in time. As a 
consequence, vaccines cannot be produced far in advance of an actual outbreak, while, at 
the same time, our modern travel habits make us vulnerable to rapid regional and global 
spread of infectious diseases.[3, 4] Another factor to consider is that, at the threat of a new 
pandemic, the go-to means of vaccine distribution, systematic mass-vaccinations through 
means of injection, poses an additional risk factor for disease transmission, as it gathers 
large groups of people in limited spaces. Additionally, administration through injection 
places high demands on vaccine purity, hygiene and access to medically trained personnel. 
The demands on the next generation of vaccines are thus clear: they should be universal, 
effective against all strains of a particular pathogen. In addition, administration should be 
fast and easy, ideally not requiring trained personnel; and, of course, they should be safe 
and effective. 
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Universal vaccines can, in principle, be created by making subunit vaccines containing 
evolutionarily conserved components of the target pathogen.[5] Additional benefits of 
subunit vaccines are that their composition and production are tightly controllable, usually 
making them safe, with few manufacturing and regulatory concerns. They are, however, 
generally less immunogenic than formulations comprising whole pathogens, with the 
consequence that they must typically be co-administered with immunostimulatory agents, 
known as adjuvants. Ease of administration could be achieved through the use of mucosal 
vaccines, which are administered through the mucous membranes, for example, orally or 
intranasally.[6] Mucosal vaccines have the additional advantage of being characterized by 
lower demands on purity compared to injected vaccines and can induce a local immune 
response at the point of entry of the disease-causing pathogen, which systemic 
administration cannot.[6] However, the mucosal immune system is not easily triggered, 
since there is a high abundance of potential immunogens, such as pollen or food proteins, 
to which tolerance is beneficial.[7] Thus, to be effective, current subunit and mucosal 
vaccine candidates often require large amounts of antigen and strong adjuvants to trigger 
the immune response.  
 
To improve the performance of mucosal subunit vaccines, the use of particulate carrier 
systems has been proposed as a promising strategy. The advantage of such systems is that 
they can improve the bioavailability of antigen, through increased delivery and/or by 
protecting it from premature degradation, and may additionally have efficient 
immunostimulatory properties in their own right.[8] Liposomes, spherical lipid bilayer 
vesicles, have been successfully used as delivery vehicles of various drugs, macromolecules 
and diagnostic agents in the clinic and are promising candidates as carriers also for 
vaccines.[9] Liposomes are vastly customizable when it comes to their composition and 
physicochemical properties, which is one of their main advantages. However, to take full 
advantage of this flexibility and to best design vaccine vectors capable of inducing an 
immune response of desired magnitude and type, it is essential to understand how the 
physicochemical characteristics of liposomes influence their immunogenicity. In order to 
address such questions, it is important to improve the understanding of the influence that 
different carrier features have on key events and processes in the development of protective 
immunity. In the process of gaining such knowledge, which would help rationalize the 
process of designing future vaccine formulations, it is the hope that one will be able to 
identify generic vaccine carrier candidates. 
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The aim of this thesis work has been twofold; firstly, to contribute to a better understanding 
of the connection between physicochemical properties of liposome-based vaccine 
formulations and the development of protective immunity. This goal was addressed 
through studying activation of the immune response as a function of the physicochemical 
properties of vaccine vectors at different levels of complexity, ranging from in vivo 
investigations of immunogenicity and protection (Paper I) to the use of in vitro cell models 
for investigation of specific key events of interest (Papers II and III). Secondly, the aim was 
to improve the possibilities to accurately describe the physicochemical properties of 
liposomes through development and application of surface sensitive techniques for 
physicochemical characterization of small-scale liposomes (Papers IV and V). Thus, this 
thesis lays in the intersection of biology, chemistry and physics. 
 
The remainder of the thesis has the following disposition: chapter 2 provides a brief 
background of the immune system and the challenges and opportunities it provides for 
vaccination. Chapter 3 introduces the concept of lipids and lipid assemblies and how they 
can be used as carrier particles, while chapter 4 provides an overview of their various 
physicochemical properties and the techniques generally available to quantify said 
properties. Chapter 5 focuses on the use of liposomes as carriers in mucosal vaccines 
against infectious diseases. Chapter 6 gives more thorough descriptions of the techniques 
used in the context of this thesis, for characterization of lipid particles as well as of particle 
uptake and antigen presentation by cells. Chapter 7 summarizes the results obtained during 
my PhD studies and, finally, chapter 8 presents the future perspectives of this work. 
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2  	  
Eliciting mucosal immunity through vaccination 
The immune system is the collection of defense responses designed for recognition of and 
protection from “non-self” elements, enabling us to resist attacks from toxins and 
pathogens, such as viruses, bacteria, fungi and worms, as well as cancer development. The 
immune system consists of a variety of cells and a multitude of molecules that are either 
secreted or presented on cell surfaces. The constituents of the immune system can be 
broadly divided into two cooperative systems that together act to prevent foreign organisms 
from entering and proliferating in the body: the innate and the adaptive immune systems. 
Together, these systems provide several layers of defense that interact through a complex 
interplay of cellular and molecular signaling and interactions.   
 
The first line of defense is the nonspecific, innate immune system. It does not, on its own, 
provide specific protection against a certain pathogen, but it is a requirement for activation 
of the adaptive immune response, which provides long-term, specific protective immunity. 
The innate immune system is composed of cells capable of clearing pathogens and infected 
cells, as well as of chemical and physical barriers designed to protect us against a foreign 
invasion. Cell types making up the innate immune system include natural killer cells, 
which lyse or induce apoptosis in infected and cancer cells. It also includes different 
phagocytes (“eating cells”), for example: macrophages, neutrophils and dendritic cells, 
which ingest and degrade viruses, bacteria, foreign particles, dead cells and cell debris, etc. 
Using pattern recognition receptors, these cells recognize conserved molecular motifs 
expressed by pathogens. Thus, the innate immune cells do not recognize individual 
bacteria or viruses, but rather react to common microbial patterns. The innate immune 
system also hosts important epithelial barriers (e.g. skin and mucous membranes), as well 
as chemical barriers, such as the enzymes and acidic environment in the stomach. An 
important contributor to the protective effect of the innate immune response is the 
complement system, which is a collection of protein and protein fragments that stimulate 
inflammatory reactions and bind to pathogen surfaces, which triggers cell lysis or promotes 
phagocytosis. A physical barrier of particular relevance to mucosal vaccination is the 
mucous membrane, which lines the body cavities and many structures of the body, such 
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as respiratory and gastrointestinal tracts, including the mouth, nose and lungs. The mucous 
membranes consist of a layer of connective tissue, known as the lamina propria, overlaid 
with tightly connected epithelial cells, which is not readily penetrable. On top of this layer 
of cells there is a layer of mucus, which is a viscoelastic, negatively charged secretion 
containing mucins and secreted antibodies (immunoglobulins; Igs)[10], as schematically 
illustrated in Figure 1. The epithelial cells are equipped with cilia: hair-like extensions that 
move in a coordinated fashion. The movement of the cilia combined with the viscoelastic 
properties of the mucus creates a directed outward flow of the mucus, trapping and actively 
transporting foreign matter in what is known as mucociliary clearance.  
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Figure 1. Example of induction of the adaptive immune response through mucosal vaccination. The vaccine 
needs to pass the mucosal barrier, for example by being taken up by a microfold cell (M cell), which transports 
it to the other side of the mucous membrane. There, it is available for uptake by dendritic cells (DCs), a 
highly specialized antigen presenting cell, which take up, process and present antigen on their surface on 
major histocompatibility complex (MHC) class I and/or II. DCs migrate to nearby mucosa-associated 
lymphoid tissue where antigen presented on MHC I activates naïve CD8+ T cells, which differentiate into 
effector and memory cytotoxic T (Tc) cells. Tc cells are specialized in killing damaged cells, such as those 
infected by viruses or bacteria, or cancer cells. Antigen presented on MHC II activates naïve CD4+ T cells, 
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which differentiate into effector and memory T helper (Th) cells. Th cells modulate the immune response 
through cytokine release. DCs additionally traffic antigen to the B cell zone. Naïve B cells are activated by 
the antigen and co-stimulation from Th cells, and differentiate into memory and effector (plasma) cells. 
Plasma cells release antibodies, for example secretory IgA, which carries out protective functions, such as 
binding to surface proteins of pathogens. 
The second line of defense, the adaptive, or acquired, immune system is the body’s specific 
response that takes longer to develop, but which, in contrast to the innate immune system, 
is highly specific to the particular pathogen. Its specificity is the result of unique receptor 
recognition of foreign molecules, antigens, by T and B cells. More specifically, B cells tend 
to recognize structural epitopes while T cells recognize linear peptides. The antigen-
specificity and formation of memory T and B cells allows the adaptive immune system to 
retain long-term recognition of the antigen, and in this way facilitate a faster and stronger 
defense upon subsequent exposures.[11] The purpose of vaccination is to stimulate 
immunological memory in order to confer long-term protection from infection without 
giving rise to symptoms of disease. 
2.1   Vaccine delivery across the mucosal barrier 
Before the adaptive immune system can be exposed to a mucosal vaccine, there is a series 
of obstacles to overcome. The innate immune system has evolved to repel and degrade 
foreign matter. Accordingly, mucosal vaccines will, upon administration, immediately 
encounter the chemical and mechanical cleansing system that is in place at most mucosal 
surfaces.[7] A first hurdle when developing a vaccination strategy is, therefore, to prevent 
degradation of the antigen, which is particularly challenging in the case of oral 
immunization.[12] This, in turn, is the main rationale for improving the resistance of 
vaccine formulations to degradation, as summarized in section 5.4. A second obstacle for 
mucosal vaccines is to deliver the antigen to the adaptive immune system, which includes 
breaching the mucosal barrier.[7, 10] There are three main strategies to increase antigen 
delivery across the mucosa. The first strategy is to increase mucopenetration, often by using 
neutrally charged and hydrophilic carrier particles in an attempt to avoid entrapment by 
the mucus (see section 5.6 for additional details). The second strategy is to increase 
mucoadhesion, in order to decrease antigen clearance rates. This is often achieved by using 
particles of a positively charged and hydrophobic nature, as discussed in sections 5.2 and 
5.6.[13] The choice between these two opposing strategies depends on the properties of the 
target mucosa. For example, mucoadhesive carrier particles can be useful when targeting 
mucosa with a slow mucus turnover rate, while mucopenetrating particles can be used for 
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traversing thick mucus layers.[14] A third strategy attempts to utilize the body’s own 
system for transport across the mucosal barrier by targeting microfold cells (M cells; see 
section 5.7). M cells are specialized in phagocytosis and transcytosis, i.e. transport through 
the interior of the cell, of macromolecules, particles and microorganisms across the follicle-
associated epithelium to the lymphoid tissues located in connection to the intestinal and 
nasal mucosa.[15] For this task, M cells have an intraepithelial pocket, where the antigens 
taken up from the luminal side are made available to antigen presenting cells (APCs) on 
the other side of the mucous membrane (Figure 1).[15] 
2.2   Antigen presenting cells: linking the innate and adaptive immune systems 
Once a vaccine formulation has crossed the barrier of the mucosa, it needs to be recognized 
by APCs, the bridge between the innate and adaptive immune responses. APCs sample 
their environment using various uptake mechanisms, including endocytosis, phagocytosis 
and macropinocytosis.[16] They distinguish self from non-self by recognizing 
evolutionarily conserved molecular structures exclusively found on pathogens and called 
pathogen-associated molecular patterns (PAMPs). Examples of PAMPs are bacterial cell-
wall components, certain lipids, for example lipid A, and different forms of bacterial and 
viral nucleic acids.[17-19] APCs use a group of receptors known as pattern recognition 
receptors for this discrimination process. These receptors include Toll-like receptors 
(TLRs), C-type lectin receptors and nucleotide-binding oligomerization domain-like 
receptors.[17-19] Ligand binding to pattern recognition receptors signals danger and starts 
a signaling cascade, which is critically required for most immune responses. In the absence 
of sufficient danger signals, the APC will induce tolerance instead of immunity. Pattern 
recognition receptor agonists are, for these reasons, often used to target vaccine delivery to 
APCs and as adjuvants to modulate the immune response (see section 5.7).  
 
A type of APC that is exceptionally efficient at taking up antigen, and which is central to 
the initiation if an adaptive immune response, is the dendritic cell (DC). Once the DC has 
taken up antigen in the presence of sufficient danger signals, it undergoes maturation, 
which leads to upregulation of the antigen-processing machinery, followed by antigen 
presentation. The antigen is processed, degraded into molecular fragments, often short 
peptides, which are displayed on the cell surface bound to major histocompatibility 
complex class II (MHC II). MHC II consists of an a- and a b-chain, which are originally 
assembled together with a chaperone protein known as invariant chain.[20] The invariant 
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chain stabilizes the MHC II and prevents premature binding of peptide to the complex. 
Following synthesis, the MHC II is delivered to the plasma membrane, from where it is 
endocytosed and routed to endosomal-lysosomal antigen-processing compartments by the 
help of targeting motifs on the invariant chain. In these processing compartments the 
invariant chain is degraded, leaving behind a small fragment known as class II-associated 
invariant chain peptide (CLIP) in the peptide-binding groove.[16] Binding of the 
chaperone protein HLA-DM (H2-M in mice) in the late endosome facilitates removal of 
CLIP and stabilizes the MHC II, as well as regulates peptide binding, leading to 
accumulation of MHC II with high-affinity peptides.[21] Finally, the peptide-MHC II 
complex is presented on the cell surface. However, the complex does not necessarily 
remain there; on the contrary, in immature DCs there is a rapid turnover of peptide-MHC 
II complexes as they are continuously marked for internalization by addition of the 
regulatory protein ubiquitin (ubiquitination) by the enzyme MARCH1.[22, 23] Upon DC 
maturation, MARCH1 expression is downregulated, leading to an increase in the stability 
of presented peptides.[22-26] Furthermore, the endocytic activity is decreased in mature 
DCs, especially of non-specific uptake mechanisms, such as macropinocytosis and 
receptor-independent phagocytosis, which involve turnover of large amounts of 
membrane.[16, 27, 28] Together, this leads to a redistribution of peptide-MHC II 
complexes from endosomal-lysosomal compartments in the immature DC to the plasma 
membrane, where they are comparatively stably presented on the mature DC.[16] Antigen 
presentation on major histocompatibility complex class I (MHC I) molecules is, in most 
cell types, reserved for endogenous peptides and used to signal normal cellular function. 
However, DCs have the ability to present also extracellular antigens on MHC I in a process 
known as cross-presentation. The importance of this process in development of cell-
mediated immunity is discussed further in section 2.3. Activated, mature DCs migrate to 
the draining lymph node where T and B cells reside in separate zones and the presented 
antigen is recognized by T cells. Initiation of a primary T cell response via activation of 
naïve antigen-specific T cells, referred to as priming of the T cells, can only be done by 
dendritic cells (DCs). For this reason, DCs are critically important for vaccination and a 
target of choice for vaccine delivery (see section 5.7).[29] There are three main DC 
subtypes: conventional DC1, conventional DC2 and plasmacytoid DC, which represent 
distinct functional lineages.[30-32] The conventional DC subsets are highly efficient at 
antigen processing; the conventional DC1 subset has a high capacity to cross-present 
antigen on MHC I, while the conventional DC2 subset presents antigen on MHC II. The 
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plasmacytoid DC subset is instead specialized at sensing and responding to viral infection 
by rapidly producing large quantities of cytokines.[31] The DC response to changes in 
vaccine vector properties was the main focus of Paper II and III, specifically effects on 
uptake (Paper III) and  antigen presentation, MHC II loading, and co-stimulation (Paper 
II). 
2.3   Inducing and tuning cell-mediated immunity 
As shown in Figure 1 and further detailed in section 2.2, DCs play a key role in the primary 
immune response, as they activate naïve T cells in the draining lymph node. The activated 
T cells then undergo strong expansion and subsequently differentiate into different 
subtypes as effector or memory T cells, which are essential for long-term immunity. A key 
event required for T cell priming is the binding of a T cell receptor to the foreign peptide in 
complex with MHC I or II molecules on the DC surface. In addition to this, T cells require 
surface-bound co-stimulatory molecules, such as CD80 and CD86, as well as released 
cytokines, all expressed by the activated DC. Together, these activation signals act in 
concert to initiate and tune a specific T cell response. Firstly, recognition of peptide-MHC 
II complexes leads to the activation of CD4+ T cells into T helper (Th) cells, whose main 
function is to organize the immune response and support B cell and CD8+ T cell immunity 
by releasing cytokines. Cross-presentation of antigens as peptide-MHC I complexes leads 
to priming of naïve CD8+ T cells, which can develop into cytotoxic T (Tc) cells that are 
important for the killing of virus-infected cells (see Figure 1).[11] Particulate delivery 
systems have been shown to increase cross-presentation efficiency, making carrier particles 
useful for vaccines for Tc cell induction.[33-35] Secondly, cytokines released by DCs 
strongly influence the type of T cells that are generated. Th cells are divided into functional 
subsets that are all generated from the naïve CD4+ T cell population. Different cytokines 
trigger polarization of the Th cells into subsets characterized by the different cytokines they 
produce and thus, which type of immune response they promote (see Table 1). Most 
notable among these subsets are the Th1, promoting cell-mediated immunity, and the Th2, 
promoting antibody-mediated, also known as humoral, immunity.  
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Table 1. An overview some of the most commonly described T helper (Th) subsets, of relevance for the 
topic.[36, 37] 
Th subset Triggering 
cytokines 
Cytokines 
released by 
subset 
Subset role 
Th1 IL-12, IFN-g IFN-g, TNF-a To activate a cell-mediated immune response 
against intracellular pathogens (e.g. viruses 
and intracellular bacteria). 
Th2 IL-4 IL-4, IL-5, 
IL-13 
To activate a humoral immune response 
against extracellular pathogens (e.g. 
extracellular bacteria and parasites). 
Th17 TGF-b, IL-6,  
IL-23 
IL-17, IL-21. 
IL-22, IL-23 
To help maintain mucosal barriers and clear 
pathogens at mucosal surfaces.  
Treg  IL-10 IL-10, TGF-b, 
IL-35 
To modulate and suppress the immune 
response to prevent excessive and harmful 
immune- and inflammatory responses. 
Tfh IL-21, IL-6 IL-21 To promote B cell differentiation and aid in 
selection of high-affinity B cells to promote 
strong, long-lived humoral immunity. 
 
2.4   Inducing humoral immunity 
Humoral, antibody-mediated, immunity is generated by B cells that develop into plasma 
cells that secrete the actual antibodies, which are large proteins able to bind to specific 
epitopes on antigens. Important effector functions of antibodies include neutralization of 
toxins and microbes, activation of the complement system and opsonization of target cells, 
a process by which a pathogen is marked for destruction by phagocytes.  
 
Antibody-antigen recognition is highly specific due to the fact that the chemical properties 
of the amino acid sequence forming the antigen-binding site of the antibody geometrically 
and physicochemically match regions on the corresponding epitope on the antigen. This 
allows formation of a multitude of electrostatic and hydrophobic interactions and 
hydrogen bonds, the sum of which is a high-affinity interaction between an antibody and 
its antigen.[11] Antibodies are classified into five different immunoglobulin classes, or 
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isotypes, according to their heavy chain, and each class is adapted to different functions in 
different compartments of the body (Table 2). Of special relevance in the context of 
vaccination are IgG, the main serum antibody; and secretory IgA, which is produced by 
plasma cells in the lamina propria in the mucous membrane.[11] It has been found that 
secretory IgA is effectively stimulated only by local mucosal immunization, highlighting 
the advantages of mucosal vaccination.  
 
Table 2. An overview of the different mammalian antibody classes, or isotypes.[11] 
Class Role 
IgG The most abundant class found in blood and extracellular fluid. Efficient opsonin 
and activator of the complement system. 
IgA Mainly found in secretions and at epithelial surfaces. It is the main antibody 
secreted by mucosal lymphoid tissues and its main function is as a neutralizing 
antibody. 
IgM The first antibody to be produced in an immune response; generally, has low 
affinity, but as it is secreted in pentamers it has high avidity. Secreted, it is found 
in blood, but generally not in tissues due to its large size. Efficient complement 
activator. 
IgE Present only in low levels in blood and extracellular fluid. Binds to receptors on 
mast cells, which induces reactions meant to expel infectious agents; such as 
coughing, sneezing and vomiting. Involved in defense against infections by 
multicellular parasites and in allergic reactions. 
IgD Expressed on the surface of mature B cells but its function is so far unknown. 
 
Antibodies are produced by B cells (see Figure 1) and exist in two forms: a free, secreted 
form and a cell-membrane bound form known as the B cell receptor. The B cell receptor is 
crucial for the activation and differentiation of naïve B cells into plasma cells and memory 
B cells, which maintain long-term protection. B cells are activated by recognition of antigen 
with the B cell receptor in the B cell zone in the lymph node; this leads to internalization 
of the antigen, which after degradation can be presented as peptide complexed with MHC 
class II molecules on the surface of the cell. Hence, also B cells can act as APCs. But, more 
importantly, the activated B cell undergoes strong expansion in the lymph node and this 
requires interactions with activated follicular helper T (Tfh) cells. B cell responses that are 
independent of this T cell help are infrequent and require bacterial antigens with repetitive 
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epitopes: certain polysaccharides, lipopolysaccharides and polymeric proteins. However, 
these responses often give rise to low affinity antibodies and no memory development.[11] 
In contrast, during T cell-dependent B cell responses, the immunoglobulin undergoes 
affinity maturation; mutations are introduced in the variable regions (somatic 
hypermutation) and affinity-based selection by Tfh cells. Thus, B cells producing higher-
affinity antibodies are positively selected in the germinal center of the B cell zone.[11] 
Furthermore, B cells undergo class switching, a process that changes the isotype of the 
antibody produced. During this process, the antibody retains its antigen-specificity while 
its constant heavy chain is changed. Since the different classes host different functions, 
with IgA antibodies particularly effective at mucous membranes, while IgG antibodies are 
preferentially found in serum, a vaccine can be designed or given by a certain route to 
stimulate more of IgA than IgG, or vice versa. 
2.5   Assessing the immune response  
Historically, vaccine development has most often focused on antibody-mediated 
immunity.[38] Indeed, antibodies are crucial for preventing infection since they can block 
the surface proteins of pathogens and thus prevent them from binding to, and entering, 
host cells. Cell-mediated immunity, on the other hand, is necessary for attenuation and 
clearance of intracellular infections and critically required for most B cell responses. 
Therefore, the aim of vaccines is to achieve both humoral and cell-mediated immune 
responses, both locally and systemically.[38] The intensity and quality of an induced 
immune response is typically assessed by measuring a set of biological markers. Different 
types of antibodies and cytokines, such as interleukins (ILs), are commonly quantified and 
indicate activity of certain cells of the immune response. Some of the more commonly used 
markers and what they indicate in the context of vaccine development are summarized in 
Table 3. In Paper I, a thorough in vivo investigation of protection and immunogenicity was 
performed, which included quantification of both antibodies and cytokines. In Paper II, an 
in vitro DC model was used and release of certain relevant cytokines was quantified. 
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Table 3. Commonly used markers of immune activation following immunization, as well as ones of 
particular relevance for the work presented in this thesis.[11, 36, 39-41] 
Marker Type of 
molecule 
Role 
IgG Antibody Indicates activation of systemic humoral immunity. 
IgA Antibody Indicates activation of mucosal/local humoral immunity. 
IFN-γ Cytokine Characteristic of a Th1 response, promoting cell-mediated immunity. 
IFN-γ is an important activator of APCs, especially macrophages, and 
inducer of MHC molecule expression and components of the antigen 
processing machinery. Induces antibody class switching and suppresses 
the Th2 response. 
IL-1β	   Cytokine Activates T cells, B cells and macrophages. Induces fever. 
IL-2 Cytokine Drives T cell proliferation and differentiation into memory and effector 
T cells. IL-2 is crucial for the survival of activated T cells and has a 
central role in the initiation of an adaptive immune response. 
IL-4 Cytokine Characteristic of a Th2 response, promoting humoral immunity.  
Activates B cells and induces CD4+ cell differentiation into Th2 cells. 
Induces antibody class switching to IgE. 
IL-6 Cytokine Activates T and B cells, drives their proliferation and differentiation, 
stimulates antibody production. 
IL-10 Cytokine Regulatory cytokine, suppresses macrophage functions and inhibits 
proliferation of, and cytokine production by, CD4+ T cells. 
IL-17 Cytokine Characteristic of a Th17 response, important for maintaining mucosal 
barriers and clearance. IL-17 has an important role in proinflammatory 
responses and induces the production of many other cytokines. 
IL-22 Cytokine Plays an important role in maintenance and defense of epithelial 
barriers. 
IL-23 Cytokine Induces proliferation of Th17 memory cells and increases IFN-γ 
production. 
IL-27 Cytokine Drives regulatory T cells of the Tr1 subtype and has an inhibitory effect 
on Th1, Th2 and Th17 subset functions, mediated by IL-10 production. 
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3  	  
Lipids and lipid self-assemblies 
Lipids are an important building block of many living organisms in that they are the main 
constituents of the cellular membranes. The membranes are thin, on the order of 5 nm 
thick, fluid films to which lipids provide a structure that allows for lateral movement of 
incorporated proteins and other biomolecules.[42] The membranes form selectively 
permeable barriers that maintain appropriate intracellular concentrations of a vast number 
of molecules and ions, thus delineating individual organelles as well as the entire cell from 
the outside.[42] Among the various lipids found in living organisms, phospholipids are the 
ones most abundantly found in cell membranes. This type of lipid is also the main 
constituent of many man-made lipid structures, including vaccine vectors.[43, 44] They 
are amphiphilic, made up of a hydrophobic tail consisting of two fatty acids linked by a 
glycerol backbone to a hydrophilic headgroup made up of phosphate and potentially 
another organic molecule (Figure 2A). Based on their headgroup, naturally occurring 
phospholipids can be sorted into 6 categories: phosphatidylcholine (PC), 
phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), 
phosphatidylglycerol (PG) or phosphatidic acid (PA). PS, PI, PG and PA are negatively 
charged while PC and PE are neutral but zwitterionic. The possibility to chemically modify 
both the head group and the tail region gives the possibility to synthesize phospholipids 
tailored to specific requirements. In this way, positively charged lipids have been created, 
for example 1,2-dioleyl-3-trimethylammonium propane (DOTAP), 1,2-dimyristoyl-
trimethyl-ammonium propane (DMTAP) and dimethyldioctadecylammonium bromide 
(DDA).  
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Figure 2. (A) Examples of lipids with different properties: 1,2-dioleyl-3-trimethylammonium propane 
(DOTAP), with a positively charged headgroup and one unsaturation in each alkyl chain, 1,2-dimyristoyl-
sn-glycerol-3-phosphoglycerol (DMPG), with a negatively charged headgroup and saturated alkyl chains, 
and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), with a zwitterionic headgroup and one 
unsaturated and one saturated alkyl chain. (B) A liposome is a spherical bilayer structure consisting of lipids 
with a cylindrical geometry. (C) Spherical or elongated micellar structures consists of lipids with a conical 
geometry. (D) Lipodisks, bilayer segments with edges stabilized by micelle-forming lipids, can be formed by 
mixing bilayer- and micelle-forming lipids at certain ratios. 
In an aqueous environment, amphiphilic molecules such as phospholipids self-assemble 
into different types of molecular assemblies where the hydrophobic parts face each other 
and form a protected compartment with the hydrophilic parts facing the aqueous 
solvent.[45] Such self-assembled amphiphilic structures exist in an equilibrium state; they 
are often not definite and constant but rather soft and fluid, with the constituent molecules 
exhibiting a high degree of movement within the aggregate and, under certain conditions, 
also between individual structures.[46-49] The size and shape of such structures are 
therefore often not sharply defined, but rather distributions that can be fairly broad.[46] 
The most energetically favorable, and therefore often most likely, structures adopted by 
amphiphiles depend on concentration and physicochemical properties of the amphiphiles 
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as well as on environmental factors such as the temperature, the ionic strength and the 
pressure, although the effect of the latter is generally small.[45] Among the properties of 
amphiphilic molecules the geometry is of particular interest as it affects the molecular 
packing and thus the type of structures, or mesophases, that are formed. There are 
essentially two basic building blocks, micelles and bilayers, that make up the different self-
assembled structures that can be formed. Micelles are spherical or cylindrical structures 
with a hydrocarbon core and a surface consisting of hydrophilic groups (Figure 2C). 
Amphiphiles with a conical geometry i.e. with large headgroup area, often due to a charged 
or bulky headgroup, and a comparatively small hydrophobic tail tend to form micellar 
structures. Amphiphiles with a tail region that is large compared to the headgroup, for 
example when the hydrophobic tail consist of two alkyl chains, have a more cylindrical 
geometry, and will tend to form bilayer structures (Figure 2B).[46] So called lipid bilayers 
consist of two layers of amphiphiles assembled with the hydrocarbon chains facing each 
other, thereby protected from thermodynamically unfavorable interactions with the 
aqueous solution by the hydrophilic headgroups. Self-assemblies containing micellar or 
bilayer structures, or both, can form large, interconnected isotropic structures or liquid 
crystalline phases, or remain as discrete entities, thereby forming particles. Such particles 
are of interest for many types of drug delivery applications and for vaccine delivery 
purposes.[50] 
 
One type of lipid-based particle commonly encountered is the vesicle, also called liposome. 
In this case, the energetically unfavorable outer edges of planar bilayer sheets are 
eliminated by forming a hollow sphere. The sphere consists of either a single or multiple 
phospholipid bilayers and liposomes are accordingly classified as unilamellar; 
multilamellar, if the bilayers are concentric; or multivesicular, if they are not. Liposomes 
where discovered in 1965 by Bangham et al. and in the 1970’s they were for the first time 
explored for drug delivery purposes and as immunological adjuvants.[51-53] Liposomes 
have since been extensively explored as vaccine vectors, with several examples being in 
commercial use and clinical trials.[12, 54, 55] Particles which contain elements of both 
micelles and bilayers may form if conical and cylindrical lipids are mixed. One such 
example of direct relevance to this thesis, is the lipodisk, which was first described by 
Edwards et al. in 1997.[56] Lipodisks are flat, single bilayer disks, comprising bilayer-
forming lipids with micelle-forming lipids eliminating the energetically unfavorable 
contribution from the high-curvature edges (Figure 2D). Lipodisks have been used as 
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membrane mimics and for drug delivery purposes but until now (in Paper II) they have, to 
the best of our knowledge, not been considered for use as vaccine vectors.[57-59]  
3.1   Functionalization and labelling of lipid particles 
The choice of lipid composition governs the type of particles formed, as well as their 
physicochemical properties. In addition to this, particles may be further customized 
through the introduction of different functional molecules. Association of such molecules 
may be done using a variety of different strategies. Hydrophobic molecules may be 
incorporated in the hydrophobic region of the particle, while hydrophilic molecules can be 
either encapsulated in the aqueous core of liposomes, or associated to the particle surface. 
Surface association can take place by covalent attachment or spontaneous association of 
the antigen to the surface through adsorption or electrostatic interaction or, alternatively, 
the functional molecule can be attached to a hydrophobic anchor that inserts into the 
particle. Having these different alternatives is especially advantageous when using lipid 
particles as vaccine carriers, as these different options allow association of a variety of 
antigens with different properties. Apart from antigen association, lipid particles may be 
functionalized with, for example, cell-targeting elements or bioadhesive polymers (chapter 
5.6 and 5.7), as well as various types of labels to enable visualization of particles or particle 
components beyond the boundary imposed by the diffraction limit. This type of 
visualization is commonly achieved by the introduction of fluorescent labels. The concept 
of fluorescence is explained in chapter 6.1, while here, the strategies available to introduce 
fluorescent labels (the generalities of which are applicable also to many other types of 
functional molecules) into lipid particles are explained and discussed. Firstly, one might 
introduce the label already when producing the particle, or alternatively, the label can be 
introduced into already finished particles. Secondly, there is a variety of different kinds of 
labels, which targets various structures or molecules, such as lipid membranes or proteins 
associated with the particle.  
 
Lipid membranes are often labelled during production by including a small percentage of 
lipids that carry a fluorescent molecule, either attached to the headgroup or to the tail 
region; alternatively, water-soluble fluorescent molecules may be encapsulated in the 
aqueous core of liposomes. Another strategy is to label the lipid particles post-production 
using a membrane-inserting dye, such as PKH; dialkylcarbocyanines, such as DiO, DiD 
and DiI; or octadecyl rhodamine B chloride. These are dyes with a lipophilic group which, 
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as the name suggests, inserts itself in lipid membranes. The precise nature of the lipophilic 
group affects how easily the dye inserts itself in the membrane and how much it tends to 
leak out or transfer. This type of dye is generally designed as a means to label cellular 
membranes, but can, with some modification to the labelling protocol, be used for lipid 
particles. An advantage of the lipophilic dyes is that one does not need to specially produce 
labelled particles, but can simply add the dye to existing ones. This is a great advantage for 
work with biological particles, such as extracellular vesicles (EVs) and viruses.[60-66] 
Additionally, one may claim some control over the directionality of the dye, as it inserts 
from the outside of the particle, while, if one forms liposomes with fluorescent lipids, 
approximately half of the fluorophores will be directed towards their interior, assuming the 
same lipid composition of the inner and outer parts of the bilayer. Disadvantages of the 
membrane-inserting dyes include the need for separation of excess dye, which tends to lead 
to some particle loss. It has also lately been revealed (by Lubart et al., in review) that the 
dye insertion efficiency may depend upon the properties of the membrane into which it is 
inserting, something that calls for careful characterization of the labelling if one wishes to 
compare different types of particles.[67] 
 
As an alternative, or complement, to labeling of the lipid membrane, any proteins 
associated with the lipid particles may also be fluorescently labelled. Proteins can be 
recombinantly produced and fused with fluorescent moieties, such as green or red 
fluorescent protein. Alternatively, post-production labelling of proteins can be done by 
covalently attaching fluorescent tags using a variety of different chemistries, or by 
immunolabelling certain epitopes with fluorescently labelled antibodies. 
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4  	  
Physicochemical characterization of liposomes 
Considering the large variety in lipids as well as the multitude of ways in which they may 
assemble, lipid particles can exhibit a wide range and combination of physicochemical 
properties. This chapter is intended to give an overview of the various physicochemical 
properties commonly (or sometimes not so commonly) reported for lipid particles in 
vaccine delivery contexts, and the techniques available to assess them. A more thorough 
description of the techniques used in this thesis is found in chapter 6. 
4.1   Size and morphology 
At first glance, size is perhaps the most intuitive of the physicochemical properties 
described here. However, there is a variety of meanings of the concept of size, dependent 
on the context and the underlying principle of the technique used for the size determination 
of the particle. 
 
Most nanoparticles are too small to be resolved using conventional light microscopy. They 
can however be still be detected and their size can be determined by other types of optical 
techniques. Dynamic light scattering is perhaps the most common particle sizing 
technique, which, similarly to the more recent nanoparticle tracking analysis (NTA) 
technique, relies on optically probing the Brownian motion of particles in suspension.[68-
70] Both techniques thus relate size in terms of hydrodynamic radius or diameter. The 
hydrodynamic radius, or Stokes radius, of a particle is not its actual physical size but the 
radius of a hard sphere with the same diffusion rate. Dynamic light scattering requires 
relatively large sample volumes and tends to provide results biased towards large particles, 
while NTA, being a single particle technique, is better at resolving polydispersity, but 
generally provides worse statistics.[68] 
 
Another sizing technique, which, similar to NTA, provides single particle information is 
tunable resistive pulse sensing. This technique is based on the Coulter principle, with 
particles in an electrolyte-containing suspension passing through a conductive pore.[71] 
The transient increase in impedance as electrolytes are displaced by the particle in the pore 
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causes a measurable drop in the current across the aperture, corresponding to the particle 
volume. A disadvantage of this method compared to direct methods, such as dynamic light 
scattering and NTA, is the need for calibration using particles of a known size. This means 
that the quality of the size determination is dependent on the particles used for calibration 
and, in extension, the method originally used to characterize them.  
 
A technique that, in addition to size, offers morphological information, for example about 
particle shape and structure, is electron microscopy.[72] Electron microscopy can be 
divided into scanning and transmission electron microscopy (TEM), both providing down 
to sub-nanometer resolution. In scanning electron microscopy, the electron beam is, as the 
name implies, scanned across the specimen and the emitted secondary electrons provide 
information about surface topography. Generally speaking, the technique demands a 
conductive sample, often requiring specimens to be coated with a thin layer of metal. In 
TEM however, it is instead the electrons transmitted through the specimen that provides 
information about the atomic number and thickness of the sample and can be used to probe 
internal structure, such as liposome lamellarity. Such measurements require specimens to 
be thin enough to be electron transparent and generally take place in vacuum, which means 
that samples in aqueous solution must be frozen (see section 6.3 for further details). Thus, 
both types of electron microscopy places high demands on sample preparation, which 
might in turn introduce artefacts.[73] Moreover, TEM resolves only structures with high 
mass and/or thickness, which, in this context, generally means that only the lipid 
structures are visualized, while any associated proteins or polymers, such as PEG, are very 
difficult to visualize. 
 
Another technique that can be used to obtain morphological information in addition to 
size is atomic force microscopy (AFM).[74] The technique utilizes a very fine tip attached 
to a cantilever. As the tip is brought into very close proximity with a surface-bound sample, 
the cantilever is deflected; the magnitude of the deflection and/or the force with which it 
interacts as it approaches is recorded, depending on the mode of operation.[75] The tip is 
scanned over the specimen in order to image its topography. AFM is, similarly to NTA 
and electron microscopy, a single particle technique, and has a resolution in the z-direction 
approximately comparable to that of electron microscopy. An advantage over electron 
microscopy, however, is that AFM can be performed on samples in the liquid state, 
allowing for studies of dynamics.  
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The structure and dynamics of molecules in liposomes can be examined using nuclear 
magnetic resonance spectroscopy. With this technique the phenomenon of nuclear spin, 
the magnetic moments of atomic nuclei, is utilized by applying a magnetic field and 
observing the frequency of the resonant electromagnetic field of the studied molecules.[76] 
31P nuclear magnetic resonance spectroscopy takes advantage of the presence of 
phosphorus in the phospholipids that generally make up liposomes (see chapter 3) and is 
especially useful as it allows for determination of liposome lamellarity.[77] To do this, the 
signal from the exterior phosphate groups are quenched using Mn2+, and the lamellarity is 
determined using the ratio of the signal before and after quenching. In general, nuclear 
magnetic resonance spectroscopy is non-invasive, highly sensitive and offers high 
resolution. However, the Mn2+ quenching-method for lamellarity determination has 
proven sensitive to the types of liposomes as well as the concentrations of Mn2+ and the 
buffer.[77] 
  
Finally, small-angle X-ray scattering detects scattering at low angles upon sample 
illumination with a monochromatic X-ray beam. The technique can be used to provide 
information about nanometer-scale structure, organization and thickness of lipid bilayers, 
as well as information on vesicle size.[78-80] A drawback of the technique is that it, in 
analogy to electron microscopy, AFM and nuclear magnetic resonance, requires 
specialized equipment and, especially, highly trained personnel. 
 
Worth noting is that single particle techniques such as NTA, tunable resistive pulse 
sensing, electron microscopy and AFM have the power to provide more information than 
ensemble average techniques. When studying single particles, one has the opportunity to 
observe and resolve different subpopulations of the property of interest. Indeed, recent 
developments in new forms of single particle detection demonstrate efforts at moving away 
from ensemble average techniques.[81-83] 
4.2   Zeta potential 
The surface charge of particles is generally assessed in terms of zeta potential, a measure 
of the electrostatic potential difference between the bulk fluid and the slipping plane at 
what is called the diffuse electric double layer that surrounds the particle (Figure 3). The 
double-layer consists of stationary (in relation to the particle) fluid and differently charged 
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ions distributed in the near vicinity of the particle surface, thus shielding the surface charge. 
The thickness of the double layer is also known as the Debye length and is defined as the 
distance from the surface where the potential has fallen to 1/e of its value at the surface.[45] 
The magnitude of the zeta potential depends on the surface charge of the particle and the 
concentration of ions within the double layer, which in turn depends on other factors, such 
as the ionic strength and pH of the dispersion medium.  
 
 
Figure 3. The zeta potential is difference in electric potential between the bulk fluid and the slipping plane 
at the limit of the diffuse electric double layer of loosely associated fluid and ions surrounding a charged 
particle. The slipping plane is located where the electric potential has dropped to 1/e of its value at the particle 
surface. 
The zeta potential is commonly assessed by electrokinetic measurements, in which motion 
of charged particles is induced by the application of an electric field. The speed of this 
motion is directly proportional to the zeta potential of the particles and can be assessed in 
conjunction with size determination using optical techniques reliant on particle mobility, 
namely dynamic light scattering and NTA (see section 4.1). Furthermore, tunable resistive 
pulse sensing (see section 4.1) can also be used for zeta potential measurements by using 
an electric field to induce particle passage through the pore. Since particle velocity in an 
electric field relates to the zeta potential, the rate of particle passage or, to gain single 
particle information, the width of the current drop caused by an individual particle passing 
through the aperture, corresponding to the particle’s speed, is recorded.[71, 84] 
4.3   Antigen content 
For lipid particles in the context of vaccine delivery, determination of the antigen load or 
content is often of interest. Broadly speaking, protein determination can be divided into 
two types, unspecific and specific protein quantification.  
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In unspecific, or total, protein quantification, no discrimination between different proteins 
in the sample is made. There is a variety of assays available for this type of protein 
detection: perhaps most notable are the Lowry,[85] the bicinchoninic acid[86] (often 
referred to as BCA) and the Bradford[87] assays, which all rely on chemical reactions 
causing a colour change. The change in colour is accompanied by a change in absorbance 
at a certain wavelength, which is proportional to the protein concentration. Worth to note 
is that, due to the differing nature of the reactions involved, the assays have varying buffer 
compatibilities. For example, the Bradford assay is sensitive to the presence of detergents, 
making it unsuitable in cases where proteins are incorporated in the lipid bilayer or 
encapsulated in the interior of lipid particles, which then need to be disrupted to release 
the proteins. Simultaneously, the Lowry and bicinchoninic acid assays are sensitive to the 
presence of chelators, such as EDTA, due to the involvement of copper ions in the 
detection reactions. A more recent protein assay, which is not sensitive to these particular 
additives, is the fluorometric 3-(4-Carboxybenzoyl)quinoline-2-carboxaldehyde (CBQCA) 
assay, which is presented in more detail in chapter 6.1.[88] Additionally, in some cases it 
is possible to detect the absorbance at 280 nm of tryptophan, tyrosine and/or disulfide-
bonded cysteine residues using UV-vis spectrophotometry, and calculating the protein 
concentration using either a standard curve or a known absorptivity value for a particular 
protein.[89]  
 
Techniques for specific protein detection often rely on immunolabelling, using antibodies 
that specifically interact with the particular protein of interest. The most commonly used 
techniques for this purpose are enzyme-linked immunosorbent assay (ELISA) and Western 
blot.[42] ELISA utilizes a detection antibody with a conjugated enzyme that converts an 
added substrate to a coloured product, which can then be optically detected. The enzyme 
can perform this conversion many times, allowing it to act as a signal amplifier. In Western 
blotting, proteins in a complex mixture are first denatured and separated based on 
molecular weight (and potentially also their isoelectric point) using gel electrophoresis. 
They are then transferred (blotted) to a membrane, where they are immunolabelled with 
one out of several detectable probes. Of course, these approaches require access to relevant 
detection antibodies, which are not available for all proteins. In the case where antibodies 
are not available, mass spectrometry is an attractive alternative.[42] In mass spectrometry, 
proteins and protein fragments are ionized and identified using their mass-to-charge ratio 
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with the help of comprehensive databases. The technique is very powerful for protein 
identification, but it is also increasingly used for quantification. It does, however, require 
specialized equipment and knowledge.  
4.4   Particle stiffness 
The deformability of lipid membranes, in terms of bending rigidity (an intrinsic property; 
not dependent on geometry), is most commonly measured on large liposomes (~10 µm in 
diameter) using either fluctuation spectroscopy, in which thermal fluctuations of lipid 
membranes are observed using optical microscopy, or through means of mechanical 
manipulation: often by micropipette aspiration, electrodeformation or through the use of 
optical tweezers.[90] Additionally, it is possible to measure bending rigidity using a 
number of scattering techniques, including diffuse X-ray scattering, neutron and X-ray 
reflectivity as well as neutron spin echo combined with dynamic light scattering.[90] 
However, in the case of small surface-adsorbed liposomes (~100-200 nm diameter) the 
internal pressure, in addition to the membrane rigidity, greatly influences the effective 
stiffness.[91] For such small liposomes the abovementioned techniques are unsuitable. 
Therefore, AFM indentation has become a popular tool to study the mechanical properties 
of small vesicles.[91-94] Furthermore, AFM used in imaging mode has been used to 
quantify surface-induced deformation of liposomes.[95] However, AFM on small 
liposomes is highly demanding in terms of skill and time. Each liposome needs to be 
individually probed, making it a work- and time-intensive technique, and limiting the 
possibilities to obtain good statistics. Thus, an interesting recent development is the use of 
multiparametric surface plasmon resonance (SPR) for the purpose of studying liposome-
surface interactions, an approach which will be expanded upon within this thesis (in Paper 
IV).[96] Multiparametric SPR is, as opposed to AFM, an ensemble average technique and 
is therefore less suitable to resolve variety within samples. It does, however, have the 
considerable advantage of being fairly rapid, both in terms of measurement and analysis. 
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5  	  
Liposomes for mucosal vaccine delivery 
Liposomes have attracted considerable interest as carriers for mucosal vaccine delivery for 
a number of reasons. First of all, the membrane composition is easily adjustable and 
membrane constituents can be synthetic or sourced from vastly different organisms, which 
invites to biomimicry. Thus, attempts have been made to enhance the immunogenicity of 
a lipid formulation by choosing membrane components with archaeal, bacterial or viral 
origins.[97-103] Conversely, by choosing endogenous lipids, vectors can be made entirely 
innocuous: biodegradable, non-toxic and non-immunogenic.[44, 104] Oftentimes, highly 
immunogenic formulations are also toxic, and creating a formulation that is effective 
without unwanted side effects is a challenge. One may therefore attempt to systematically 
address which particular physicochemical properties are at the root of the immunogenic 
effect to be able to create formulations with the desired properties but without toxic 
constituents. 
 
An advantage of lipid-based vaccine formulations is that the physicochemical properties of 
the lipid particles are vastly adjustable. The membrane properties can be tuned by altering 
the lipid composition: the surface charge of the particles is largely affected by the 
characteristics of the lipid headgroup, and the degree of hydrophilicity can be tuned by 
addition of polymers such as poly(ethylene glycol) (PEG).[9, 105] The headgroup charge, 
along with the length and degree of saturation of the alkyl chains of the tails, further 
influences the transition temperature of the lipids, which in turn determines whether a lipid 
membrane exists in a gel or fluid phase state at a certain temperature. Moreover, if a 
membrane consists of a mixture of lipids, phase separations can occur, resulting in 
heterogeneous distribution of different lipids. The stability of a membrane, i.e. its resistance 
to degradation, is affected by its fluidity and permeability as well as its bending rigidity, 
which are in turn influenced by the same lipid characteristics. Incorporation of cholesterol 
is a common way to modulate the membrane permeability, fluidity and rigidity, which 
influence the liquid-to-gel phase transition temperature and stability of the formulation.[50, 
106] Liposome size and morphology/lamellarity can be tailored by altering the 
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manufacturing method; for lipodisks, the size is affected by both method and 
composition.[106, 107] 
 
An inherent property of lipid particles, which makes them useful as antigen carriers, is that 
they contain both hydrophobic and hydrophilic regions, allowing for a variety of coupling 
strategies. Hydrophobic peptides or proteins can be incorporated into the hydrocarbon 
center of bilayers or micelles, while hydrophilic molecules can be coupled to the surface of 
lipid particles or encapsulated in the aqueous core of liposomes (see Figure 4C). In cases 
where the lipid particles are included in a vaccine formulation solely as adjuvants, they 
may simply be co-administered with the antigen. 
 
With the possibility to tailor both preparation method and composition, as well as ways of 
incorporating antigen in the formulation, there are virtually endless possibilities in the 
production of lipid structures with varying properties. However, it still remains to be 
understood why the immune response is modulated differently by different liposomal 
formulations, and which properties are decisive for the outcome. This is a particularly 
challenging task as it is inherently difficult to isolate the contribution of different properties, 
as changing one property usually influences one or several others. For instance, when 
varying the surface charge by altering the lipid composition one may inherently affect other 
properties, such as membrane fluidity and rigidity, as well as their resistance to enzymatic 
degradation, etc. Hence, it may be difficult to directly assess the influence of changing 
different physicochemical properties of carriers on the immune response. Nevertheless, 
attempts have been made to systematically study the influence on immunogenicity that the 
physicochemical properties (Figure 4) liposomes used in mucosal vaccines against 
infectious diseases have, as summarized in further detail below starting with size and 
morphology (section 5.1), followed by sections addressing zeta potential (section 5.2), 
antigen localization (section 5.3), liposome resistance to degradation (section 5.4), 
liposome stiffness (section 5.5), modifications to increase bioavailability (section 5.6) and 
cell-targeting modifications (section 5.7).  
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Figure 4. Schematic representations of the physicochemical properties of liposomes that are reviewed here. 
(A) Liposome size and morphology/lamellarity are difficult to very tightly control but have, in some 
instances, been investigated. (B) The impact of zeta potential, the difference in electrostatic potential between 
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the bulk fluid and the slipping plane of the particle, has been extensively examined. (C) The role of the 
localization of the antigen: on, inside or beside the liposome, has been investigated. There are several modes 
of antigen association to liposomes. Firstly, antigens may be linked to the surface via covalent attachment or 
through the use of a hydrophobic anchor that inserts into the membrane. Alternatively, the antigen may 
associate via adsorption or electrostatic interactions with a particle of opposite surface charge. If the antigen 
contains hydrophobic regions, these may insert into the lipid membrane and thus couple the protein to the 
liposome. Furthermore, antigens may be encapsulated in the aqueous core of the liposome. Liposomes may 
also simply be simply admixed with the antigen. (D) The lipid composition may impact the liposomes’ 
resistance to degradation in biological fluids, as well as their stiffness/bending rigidity and fluidity. (E) Cell-
targeting modifications to liposomes to increase their association with cells of interest can be done, for 
example, by attaching pathogen-associated structural motifs (PAMPs), such as lipid A (in inset, see section 
2.2 for further information), or by targeting cell-specific surface proteins using antibodies (e.g. anti-CD103 
or anti-DEC205). (F) Modifications aimed at increasing either mucoadhesion or mucopenetration both have 
the final goal of increasing bioavailability and are commonly done by either fully coating liposomes with 
polymers or polyelectrolytes, or by adding individually coupled polymers, often some form of poly(ethylene 
glycol) (PEG). 
5.1   Size and morphology 
A broad range of liposomes of varying morphologies and with varying sizes (Figure 4A) 
has been proposed for vaccine delivery and the different particles have been found to 
induce different effects following mucosal immunization. However, the influence of these 
parameters on liposome immunogenicity has rarely been systematically investigated and 
unfortunately details about liposome morphology are not routinely reported. The few 
studies reporting on the effects of morphology in general, and lamellarity in particular, on 
immunogenicity show inconclusive results. A comparative study between unilamellar 
liposomes made from archaeal polar lipids (archaeosomes) with an average diameter of 
100 nm and large (on the scale of tens of µm) irregularly shaped liposome aggregates clearly 
indicated better immunogenicity for the aggregates.[98] Another study reported that oral 
administration of a “double liposome”, consisting of small (~250 nm) liposomes made 
from SoyPC, dipalmitoylphosphatidylcholine (DPPC), cholesterol and stearylamine 
encapsulated into a bigger (1 to 10 µm) outer liposome made from 
dimyristoylphosphatidylcholine (DMPC) and 1,2-dimyristoyl-sn-glycerol-3-
phosphoglycerol (DMPG), was found only marginally more immunogenic than small 
liposomes.[111] Additionally, a study using liposomes made from DPPC, DDA and 
cholesterol with sizes ranging from 70 to 1000 nm for intranasal immunization of mice 
similarly showed no significant effect of size on immunogenicity.[112] 
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Constructing homogeneous, strictly monodisperse liposomes of controlled lamellarity is 
technically challenging; typically, liposomes in a range of sizes and various degrees of 
lamellarity may co-exist, making interpretations of experimental results difficult. Recent 
advances in the production of tightly size-controlled liposomes may allow for more 
accurate comparisons of the influence of size, lamellarity and overall structure in the 
future.[113] 
5.2   Zeta potential 
One of the most commonly explored parameters in the context of mucosal vaccine delivery 
is the charge, zeta potential, of the liposome (Figure 4B). The magnitude of the zeta 
potential depends on the properties of the particle, but also other factors, such as the ionic 
strength and pH of the dispersion medium. This must be kept in mind when comparing 
zeta potential values reported in different studies and under different conditions, as well as 
when considering the relevance of this parameter in in vitro and in vivo studies.  
 
Because the cell surface as well as the mucus coating of the mucous membrane is negatively 
charged, positively charged liposomes will generally exhibit stronger interactions with the 
cell membrane as well as an increased mucoadhesion.[13, 44] The latter leads to reduced 
clearance rate, i.e. slower removal from the mucous membranes. This may be beneficial 
for antigen delivery as both increased interactions with the cell membrane and prolonged 
exposure time of the antigen at the mucosal surface, are thought to lead to increased 
cellular uptake of antigen and stronger immune responses.[114, 115] Indeed, cationic 
liposomes were found to effectively deliver antigen to both mucus and APCs as shown in 
an in vitro model of the airway epithelium with liposomes made with 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC)/trehalose 6,6-dibehenate (neutral) and 
DSPC/trehalose 6,6-dibehenate/DDA (positive) with varying amounts of the positively 
charged DDA.[116] Moreover, cationic liposomes consisting of DOTAP/cholesterol, 
DMTAP/cholesterol or, most prominently, the polycationic sphingolipid ceramide 
carbamoyl-spermine (CCS) and cholesterol were shown to effectively stimulate systemic 
and mucosal humoral and cellular immune responses after intranasal immunizations in 
mice.[108] In contrast, neutral liposomes with DMPC or anionic liposomes with 
DMPC/DMPG were comparably ineffective as immunogens.[108] While a positive 
charge appeared to increase the immunogenicity of liposomes in these cases, this may not 
always be true. In fact, there are scientific reports suggesting that negatively charged 
	  	   34	  
liposomes are more immunogenic than both zwitterionic and positively charged liposomes 
and it has even been postulated that anionic liposomes could exert an immunosuppressive 
effect on alveolar macrophages (a type of macrophage found in the alveoli of the lungs, see 
chapter 2), and in this way promote an enhanced humoral immune response.[109, 117-
120] Hence, it appears that several mechanisms can be modulated by the charge of the 
liposome. In particular, the influence of charge on immunogenicity may be highly 
dependent on the administration route, where different microenvironments with varying 
electrostatic properties may be encountered.  
5.3   Antigen localization 
There are many ways of incorporating antigens into liposomes. This raises the question 
whether some strategies are more effective than others in the context of optimizing the 
immunogenicity of the liposome formulation. Antigens can be hosted in the aqueous core 
of the liposome, inserted into the hydrophobic part of the membrane or bound to the 
surface by covalent bonds or intermolecular forces (Figure 4C). Hence, a plethora of 
combinations exist and those could be used, in combination with various lipid 
compositions, to enhance resistance against antigen degradation or to facilitate antigen 
uptake. Thus, the liposome formulation may be tailored for specific needs and purposes. 
If an oral vaccine is to be designed, one may hypothesize that encapsulating the antigen 
inside the liposomes is an effective strategy to prevent enzymatic degradation. However, 
by hiding the antigen in the liposome, the immunogenicity may be compromised because 
the antigen will not be immediately accessible for APCs. Therefore, choosing how to 
physically incorporate the antigen in the liposome may have critical consequences on the 
immune response. Unfortunately, such aspects have not been addressed in a systematic 
manner thus far. Studies report that when administered orally, encapsulated antigen may 
more effectively stimulate local IgA and serum IgG antibody responses compared to when 
soluble antigen is admixed with the liposomes.[121, 122] On the other hand, following 
intranasal administration, a mixture of antigen and liposomes has been quite effective even 
compared to liposome-encapsulated antigen.[108, 118] Interestingly, liposomes have been 
found to exert an immuno-enhancing effect even when administered 48 hours prior to the 
antigen.[118] Furthermore, surface-bound antigen has been found to be more 
immunogenic than encapsulated antigen following intranasal immunization.[119] These 
observations suggest that the intranasal route is less sensitive to antigen degradation 
compared to the oral route. Thus, depending on the route of administration, it seems clear 
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that antigens may or may not be immunogenic when exposed, and for many formulations 
it may, in fact, be advantageous to have a combination of surface-bound and encapsulated 
antigens. This may also apply to molecular adjuvants; it was found that cholera toxin B-
subunit (CTB) adjuvant bound to the surface of the liposome was more effective compared 
to when encapsulated in the liposome.[123] Furthermore, it has been observed that by 
altering the lipid-to-antigen ratio, the systemic and mucosal as well as the humoral and 
cellular immune responses can be differentially induced.[108, 124] Thus, it is likely that 
the immune response following liposome administration is susceptible not only to the 
choice of antigen and adjuvant but also to their relative proportions and localization in the 
liposome. 
5.4   Liposome resistance to degradation 
The lipid composition (Figure 4D) is known to influence the stability, i.e. resistance to 
degradation, of the liposome; a more stable formulation might lead to a larger amount of 
bioavailable antigen and potentially also to a depot, i.e. slow release, effect. Han et al. 
made liposomes from various combinations of cholesterol, DPPC, 
dipalmitoylphosphatidylserine (DPPS) and DSPC and found that certain combinations 
decreased leakage of encapsulated carboxyfluorescein in different solutions simulating 
conditions in the gastrointestinal tract.[102] Liposomes with DSPC, having a higher 
transition temperature, were more stable in vitro and likely protected antigen better from 
degradation in the gastrointestinal tract.[102] As aforementioned, using archaeal lipids, 
liposomes can be made more immunogenic and archaeosomes were found considerably 
more potent than liposomes made with Egg phosphatidylcholine (EPC)/cholesterol at 
inducing antigen-specific IgG and IgA antibodies following oral administration in a mouse 
model.[97] This was attributed by the authors to an increased stability in the 
gastrointestinal tract and to the fact that the archaeosomes were better retained in the 
intestine. [97] However, the difference may also partly reflect the fact that the 
archaeosomes were negatively charged while the EPC/cholesterol-liposomes were neutral 
and, as discussed in section 5.2, negatively (or positively) charged liposomes are generally 
more immunogenic than neutral ones. 
5.5   Liposome stiffness 
Parameters that affect the stability to degradation of liposomal formulations (lipid 
transition temperature, inclusion of cholesterol) generally also influence the membrane 
bending rigidity, or deformability (Figure 4D). The role of membrane rigidity on mucosal 
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vaccination outcomes has only been marginally investigated [108, 125] and studies on the 
impact of this parameter on the immunogenicity of injected vaccine formulations has had 
mixed results.[108, 126-134] Complicating investigation of this topic is the fact that, as one 
approaches nanoscopic length scales, the effective stiffness does not depend only on the 
membrane rigidity, but also on the membrane strain and internal pressure arising in 
response to the change in internal volume upon liposome deformation.[91] Moreover, 
functionalization of the liposome with polymers, antigens and cell-targeting ligands further 
complicates any prediction of effective liposome stiffness. In addition, experimental 
quantifications of the stiffness of nanoscopic vaccine liposomes are not trivial (see section 
4.4), a fact that stands in the way of systematic investigation of the impact of this property. 
Indeed, it was in an attempt to address this lack of methods for convenient investigation of 
liposome stiffness that we undertook the work presented in Paper IV. However, even with 
accurate quantification of stiffness, predicting its implications on vaccine vector 
interactions with cells and tissues is not inconsequential. It has been theorized that high 
liposome flexibility may facilitate cell surface attachment and may, for this reason, be 
beneficial from an antigen delivery standpoint.[125] Simultaneously, theoretical[135-137] 
and experimental[131, 137] investigations  suggest that high particle stiffness should 
improve (or decrease[138]) cellular uptake. It would thus appear that liposome stiffness is 
likely a key factor governing the binding and uptake of liposomes by cells. This prompted 
us to investigate the influence of this parameter on uptake (Paper III) and antigen 
presentation (Paper II) by APCs. 
5.6   Modifications to increase bioavailability 
The microenvironment at mucosal surfaces often promotes a high clearance rate of 
liposomes. Therefore, various strategies have been tested to enhance mucus penetration or 
to increase antigen-carrying liposome-to-cell membrane adhesion in order to increase the 
bioavailability of the vaccine antigens (Figure 4F). Layer-by-layer deposition of 
polyelectrolytes onto the liposomes, for example, has been used as a liposome-stabilizing 
approach which resulted in higher specific IgA and IgG antibody levels as well as an 
increased T cell response.[139] Poly-vinyl alcohol or chitosan have been tested to enhance 
bioadhesive properties of the liposomes and it has been observed that chitosan-loaded and 
-coated liposomes, indeed, increased IgG antibody responses.[140] Chitosan is a positively 
charged polysaccharide that can form strong electrostatic interactions with cell surfaces 
and mucus and, therefore, increase retention time and facilitate interactions between the 
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liposome and APCs in the mucous membrane.[141] Additionally, chitosan can transiently 
open tight junctions between epithelial cells to allow for transmucosal transport.[142, 143] 
Chitosan-modification of liposomes is accordingly a popular strategy for delivery of 
peptidic antigens.[140, 144-146] In fact, chitosan-coated liposomes have been shown to 
give better serum IgG antibody levels compared to liposomes coated with other 
bioadhesive polymers, such as hyaluronic acid- or carbopol, and host better 
immunogenicity than uncoated negative, neutral or positively charged liposomes.[145]  
 
Considerable attention has been given to studying how liposomes are retained by and/or 
taken up across the mucous membranes. Liposome interactions with the intestinal mucosa 
have been studied in vivo and ex vivo as well as using various in vitro models.[97, 139, 147, 
148] The latter models have addressed whether passage of liposomes through the tight 
junctions of epithelial cells can be achieved. Indeed, tight junctions were reported to be 
open when using PC/cholesterol-liposomes or liposomes coated with extract from Tremella 
fuciformis.[148] Enhanced immune responses were also observed with mucus-penetrating 
liposomes made with PEG or the PEG-copolymer Pluronic.[146] Significantly higher 
specific IgA and IgG antibody levels were found with PEGylated than non-PEGylated 
liposomes. Modifications with PEG or Pluronic F127 also proved useful in preventing 
liposome aggregation through steric stabilization to obtain small (< 200 nm) chitosan-
coated liposomes. In fact, these shielded chitosan-coated and PEGylated liposomes 
yielded the highest functional serum antibody titers and the strongest IgA responses of all 
the formulations tested in this particular study.[146]  
5.7   Cell-targeting modifications 
In the context of carriers for vaccine delivery, one of the most explored modifications is 
aimed at targeting the delivery of liposomes to subsets of cells that express a comparatively 
large number of predefined receptors or binding sites. This is achieved by equipping the 
liposomes with various targeting elements to increase the number of liposomes delivered 
to the target cell subset (Figure 4E). For example, targeting components may be added to 
enhance the uptake by APCs or the penetration of the liposome through the mucous 
membrane. Additionally, the target receptor may be directly involved in immunological 
signaling and thereby enhancing of the immunogenicity of the liposomes.  
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APCs in the mucosal tissues have a high density of surface GM1 and the strongly GM1-
ganglioside-binding molecule CTB has been reported to enhance liposome 
immunogenicity.[101, 149, 150] DCs have similarly been targeted by use of mannosylated 
lipids or anti-CD40 antibody-coated liposomes, which promoted a stronger immune 
response.[151, 152] Another popular target on immune cells are TLRs, a type of pattern 
recognition receptor used by phagocytes to recognize PAMPs, i.e. pathogen-associated 
structural motifs. For instance, when monophosphoryl lipid A, acting through the TLR4 
receptors, was added to liposomes, their ability to stimulate the innate immune response 
was dramatically improved.[101, 102, 153] Other TLR agonists or Escherichia coli heat-
labile toxin have also been used in combination with liposomes as adjuvants.[99] 
Furthermore, liposome linking of CpG, which acts through TLR9 signaling; or Bordetella 
pertussis filamentous haemagglutinin, whose effects include binding to macrophage 
integrins, have been found to enhance immunogenicity.[154, 155] Targeting macrophages 
via C-type lectins by galactosylation of liposomes resulted in higher specific IgA and IgG 
antibody levels compared to unmodified liposomes.[156] Another strategy to target 
macrophages is to incorporate PS. PS is naturally exposed on the surface of cells 
undergoing apoptosis and in this way liposomes containing PS may trigger phagocytosis 
by macrophages. Accordingly, it has been found that liposomes containing DPPS induced 
stronger IgA responses compared to formulations without DPPS.[153] Combinations of 
both DPPC/DMPG and DPPC/PS have been found effective at targeting liposomes to 
macrophages, and DPPC/DMPG was the only formulation to induce a significant 
antibody response following oral immunization.[121]  
 
Another strategy aims at making uptake through mucous membranes more effective by 
targeting M cells in the follicle-associated epithelium, the thin epithelial cell layer that is 
responsible for antigen-uptake from the luminal side. Accordingly, the lectin Agglutinin I 
from Ulex europaeus was shown to improve M cell-mediated transport across the intestinal 
epithelium.[147, 157, 158] Similarly, liposomes functionalized with antibodies have been 
found to enhance binding to M cells, and as a result increased levels of IgG, IL-2 and IFN-γ were shown following intranasal immunization.[110] 
 
Many strategies have been proposed to achieve cell-targeting of liposomes, with varying 
degrees of improved function. A plethora of possibilities can be explored when it comes to 
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targeting liposomes to the cells of the mucosal immune system. The combination of 
analytical tools for nanoparticle characterization with suitable in vitro and in vivo assays 
will greatly help identify the relative importance of liposome targeting and other properties 
discussed in this chapter and how they can influence the immune response. 
5.8   Concluding remarks  
To conclude this chapter, it is clear that the design of a lipid-based vaccine formulation is 
complex and, needless to say, it is important to consider all of its properties. Thus, 
liposome size, lamellarity and surface charge as well as lipid composition and rigidity of 
the membrane can all influence the immune response following vaccination. Importantly, 
the choice of antigen, with its own inherent physicochemical properties, as well as the 
position of the antigen and any molecular adjuvant in the liposome affect the function of 
the formulation. Furthermore, the antigen/lipid ratio and properties of the added adjuvant 
are also important parameters that change the immunogenicity of the liposome. In addition 
to this, it should be added that care must be taken when drawing general conclusions based 
on parallels between different studies, since it is often the case that liposome characteristics 
other than those directly investigated are inadequately reported. This is important because 
changing one parameter may completely inverse the effect of another, as specifically 
discussed in reference [159]. Thus, systematically varying individual properties is indeed a 
useful approach, but one must not forget that a nanoparticle is characterized by a range of 
properties and that varying one may influence the biological response to others. 
 
Despite this complexity, it is clear from the literature that lipid carriers can be used to, in a 
fairly controlled manner, modulate the immune response in a wide variety of model 
systems. It remains, however, to be elucidated by which mechanism their 
immunomodulation takes place and therefore, how to tune their properties in order to alter 
their effect. What are then the ideal properties of a strong and effective lipid-based mucosal 
vaccine? This question is indeed difficult to answer, not only because the underlying 
mechanisms remain to be investigated, but also because there is currently no standardized 
procedure to assess the potential of lipid carriers in the context of vaccination. While 
specific aspects of the mode of action of liposomes are often studied, for example stability 
in simulated intestinal fluids, mucoadhesion and APC uptake, more systematic 
examinations of how different parameters influence different parts of the process remains 
to be seen. Especially the mechanism behind the immunostimulatory properties of 
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liposomes, unrelated to their role as carriers, is poorly understood. However, the most 
fundamental step towards rational design of lipid-based vaccine particles would be to 
develop a systematic protocol for measuring vaccination outcome as well as for the 
physicochemical characterization of the particles themselves. Moreover, identifying the 
immune responses that elicit mucosal protection would aid the rational design of effective 
mucosal vaccines. One aim of this thesis work is to take steps in this direction.  
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6  	  
Experimental techniques 
The experimental techniques used in this work can be divided into two main categories: 
techniques used for physicochemical characterization of the lipid nanoparticles and 
techniques used for characterization of the elicited immune response, in particular uptake 
and antigen presentation by DCs. The former includes methods for quantification of 
protein content (section 6.1), particle size determination (section 6.2), examination of 
particle morphology (section 6.3) and zeta potential (section 6.4). Section 6.5 introduces 
surface plasmon resonance as a tool to study surface-induced deformation, and thus 
characterization of the mechanical properties, of liposomes. To characterize the elicited 
immune response, light microscopy is the technique of choice to follow the details of 
particle-cell membrane interactions and uptake (section 6.6), while flow cytometry has 
been used to quantify antigen presentation as well as uptake (section 6.7). 
6.1   Fluorometry for protein quantitation 
Fluorometry relies on the concept of fluorescence, which is commonly visualized using a 
Jablonski diagram, as seen in Figure 5A.[76] In fluorescence, a molecule known as a 
fluorophore has a high likelihood to emit light when excited by incoming light of 
appropriate wavelength. Light of this wavelength consists of photons with an energy 
content that corresponds to the energy gap between the ground state (S0) and a higher, 
excited, state (S1 or S2) of the fluorophore. When such a photon hits the fluorophore, the 
molecule is excited to the higher energy state. The higher energy state is not stable and 
hence the molecule rapidly returns to the ground state and in doing so light of a lower 
energy is emitted, as some energy is lost in thermal processes.[76] The energy, E, of a 
photon is given by: 𝐸 = #$%  (6.1) 
where h is Planck’s constant, c is the speed of light and λ is the wavelength. Hence, the 
emitted lower energy photon will generally have a longer wavelength. The difference 
between the peak excitation wavelength and the peak emission wavelength of a certain 
fluorophore is termed Stoke’s shift.[160] A common method used to determine emission 
spectra for fluorophores and to generally quantify fluorescence is fluorometry. The basic 
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components of a fluorometer are: a light source, a specimen chamber or sample holder and 
one or several photodetectors such as photomultipliers and charge-coupled device (CCD) 
cameras. Additionally, there are commonly monochromators or filters to select specific 
excitation and emission wavelengths.   
 
Fluorometry can be used to determine protein content either by utilizing inherently 
fluorescent residues such as tryptophan or by the use of assays in which a fluorescent tag 
is introduced. The CBQCA assay is one such assay in which the non-fluorescent molecule 
3-(4-Carboxybenzoyl)quinoline-2-carboxaldehyde (CBQCA) reacts with primary amines 
in the presence of cyanide to form a highly fluorescent derivative (Figure 5B).[88] After 
acquiring a calibration curve, the magnitude of the emitted fluorescence can be used as a 
measure of total protein content of a sample. 
 
 
Figure 5. (A) The principal of fluorescence illustrated with a Jablonski diagram. A fluorophore is excited 
from the ground state S0 to the excited state S1 through absorption of light. During relaxation back to the 
ground state, light of a lower energy is emitted. (B) The reaction of the non-fluorescent molecule 3-(4-
Carboxybenzoyl)quinoline-2-carboxaldehyde (CBQCA) with primary amines in the presence of cyanide to 
form a highly fluorescent derivative used to quantify total protein content. 
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6.2   Nanoparticle tracking analysis 
Nanoparticle tracking analysis (NTA) is a nanoparticle sizing and concentration 
determination technique that relies on visualizing particles in solution undergoing 
Brownian motion.[70] During a measurement, a laser beam is passed through the solution 
containing the nanoparticles, which are visualized through light scattering or fluorescence 
and whose diffusion is recorded using an optical microscope equipped with a camera 
(Figure 6). Particles in solution undergo Brownian motion in three dimensions. Under the 
assumption that the motion is uniform in all directions, the captured two-dimensional 
motions of the particles are tracked by the NTA software in order to determine their 
diffusion coefficients D from the relation:  𝐷 = '()(*+)-)(.))/01*+  (6.2) 
where x is the mean squared displacement in two dimensions during the time Δt.[161] 
Assuming spherical particles, the hydrodynamic radius r is given by the Stokes-Einstein 
equation: 𝑟 = 3456789 (6.3) 
where kB is the Boltzmann constant, T is the temperature in Kelvin and η is the solvent 
viscosity.[70] The hydrodynamic radius, or Stokes radius, of a particle is not its actual 
physical size but the radius of a hard sphere with the same diffusion rate. This is important 
to keep in mind when working with non-spherical particles. 
  
NTA can be used for size determination of particles with diameters between approximately 
30 to 1,000 nm, with the lower limit being determined by the difference between refractive 
index of the particles and the surrounding medium.[68] 
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Figure 6. Schematic of a nanoparticle tracking analysis (NTA) setup. Particles undergoing Brownian motion 
in solution are visualized through scattering of laser light. Their motions are tracked using specialized 
software in order to determine their diffusion constant and hydrodynamic diameter. 
6.3   Cryogenic transmission electron microscopy 
Transmission electron microscopy (TEM) is a high-resolution imaging technique in which 
the image contrast is generated by the scattering of electrons when they encounter 
structures with high atomic number within the specimen. The instrument consists of an 
electron source emitting an electron beam, that may be focused onto the specimen with 
electromagnetic lenses, and a detector, commonly a CCD camera (Figure 7A).[72, 162] 
The imaging is by necessity performed in vacuum to avoid scattering of the electron beam 
by air. The analyzed samples are thin, 20-90 nm, and negative staining is often applied to 
increase the contrast. Negative stains generally consist of a salt of a heavy metal with a 
high atomic number (42-92) that forms a thin glassy film on top of the specimen.[72] 
Conventional TEM on hydrated systems is however prone to artifacts due to staining and 
shrinking due to drying, which affects the perceived morphology of the specimen.[72] 
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Figure 7. (A) Schematic representation of cryogenic transmission electron microscopy (Cryo-TEM); 
scattering of electrons is used to visualize structures of high electron density in a cryopreserved specimen. (B) 
In a common type of cryopreservation, the specimen, in solution, is applied to a lacey carbon film mounted 
on a copper grid. The supported specimen is plunged into a cryogen leading to formation of vitreous ice, 
preserving the morphology of fragile structures.  
To overcome these limitations, cryogenic TEM (Cryo-TEM) relies on cryopreservation of 
the sample prior imaging to minimize artifacts. The sample preparation is aimed at creating 
vitrified specimens that maintains their structural integrity, generally through plunge 
freezing of thin films or cryo-sectioning of bulk samples.[72] Plunge freezing is a fast and 
fairly straightforward method in which a small amount of sample in liquid suspension form 
is added to a supporting substrate, often a lacey carbon film supported by a copper grid. 
The sample is blotted with filter paper so that only a thin film remains on the substrate and 
is then plunged into a cryogen with high heat capacity, such as liquid ethane at around -
183 °C. Due to the very rapid freezing rate, the liquid suspension vitrifies instead of 
forming crystalline ice, thus keeping the structures within intact (Figure 7B). The vitrified 
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samples are transferred to the electron microscope’s cryoholder under liquid nitrogen and 
are viewed at around -173 °C under high or ultra-high vacuum.[72] 
 
Due to the thinness of the film formed through this preparation method, it may be difficult 
to visualize larger structures. Furthermore, the elements comprising biomacromolecules 
and polymers, such as proteins and PEG, generally do not scatter enough to provide 
sufficient contrast to be readily visible with Cryo-TEM.[72] Cryo-TEM of protein- and/or 
polymer-conjugated lipid particles therefore gives information about the size and 
morphology of the lipid structures only, unless additional labeling is performed. It is 
important to note that since Cryo-TEM gives information about the physical size of 
particles, it can be misleading to directly compare sizes measured from Cryo-TEM images 
to data obtained with other sizing techniques that measures the hydrodynamic size, such 
as NTA or dynamic light scattering.  
6.4   Laser Doppler electrophoresis 
The charge of particles is commonly assessed by measuring their electrophoretic mobility, 
i.e. their velocity in an electric field.[45] This measure is independent of shape and size and 
can be assessed using laser Doppler electrophoresis (LDE). An LDE instrument generally 
consists of a laser providing collimated light that is split into two beams: the scattering 
beam and the reference beam (Figure 8A).[163] The scattering beam enters the scattering 
volume, an electrophoretic cell that contains the specimen, a suspension of particles, which 
scatters the incoming light. The movement of the particles undergoing electrophoresis 
causes a shift in the frequency Δf of the scattered light compared to the reference beam due 
to the Doppler effect according to: ∆𝑓 = 2𝑣 ∙ ?@A	  (C/E)%  (6.4) 
where v is the particle velocity, λ is the wavelength of light used and θ is the scattering 
angle.[163] The light scattered at the angle θ is combined with the reference beam before 
arriving at the detector. Analysis of the Doppler shift can be made using phase analysis 
light scattering in order to deduce the electrophoretic mobility of the particles. 
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Figure 8. (A) Schematic representation of a Laser Doppler electrophoresis (LDE) instrument; laser light is 
split into a reference beam and a scattering beam, which is scattered by the particles undergoing 
microelectrophoresis. The frequency shift between the reference beam and the light scattered at angle θ, due 
to the Doppler shift is used to deduce the electrophoretic mobility of the particles which is used to determine 
the zeta potential. (B) The zeta potential is the electric potential, not at the particle surface, but at the slipping 
plane at the edge of the diffuse electric double layer comprising ions loosely associated with the particle (see 
section 4.2). 
The oscillating electric field applied during LDE causes the particles to move at a velocity 
that is proportional, not to the charge directly at the particle surface, but rather to the zeta 
potential, which is the electrostatic potential at the slipping plane at the edge of the diffuse 
electric double-layer surrounding charged particles (Figure 8B, see section 4.2 for details). 
The zeta potential ζ can be calculated using the Henry equation: 𝜁 = GH8EIJKL	   𝑓(𝜅𝑎) (6.5) 
where μ is the electrophoretic mobility, ε0 is the permittivity of vacuum, η and ϵa are, 
respectively, the viscosity and the dielectric constant of the dispersion medium and a is the 
particle radius.[164] f(κa) is Henry’s function which depends on the Debye length κ-1. The 
magnitude of both the Debye length and the zeta potential do not only depend on the 
particle charge, but also on the ionic strength and pH of the medium in which the particles 
are dispersed.[45] In cases where the particle radius is much larger than the Debye length 
(κa >> 1), the Henry equation can be simplified using the Smoluchowski approximation 
of f(κa) = 1.5, giving: 𝜁 = H8IJKL	   (6.6) 
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.[164, 165] At physiological ionic strength, the Debye length is on the order of nanometers, 
so this approximation is thus often suitable.[45]  
6.5   Surface plasmon resonance 
Surface plasmon resonance (SPR), a surface sensitive technique utilizing optical excitation 
of surface charge density waves of free conduction electrons at a metal-dielectric interface, 
was first described by Kretschmann[166] and Otto[167] in the late 1960s. The technique is 
commonly used for biosensing following the work of Liedberg et al. in the early 
1980s.[168] Commercial instruments often utilize the Kretschmann configuration[166] 
which, as depicted in Figure 9, consists of a glass sensor slide coated with a metal layer, 
typically gold, in contact with the ambient medium. The use of a thin enough gold layer 
enables p-polarized laser illumination through the glass to affect the metal-ambient 
interface. The dispersion relation for a surface plasmon propagating along this interface 
can be written as 𝑘PQ = R$ S TKL + TKVW-T/E (6.7) 
where w is the angular frequency, c the speed of light, ϵa the dielectric constant of the 
ambient medium and ϵm the real part of the complex dielectric function of the metal. 
Excitation of the surface plasmon occurs when ϵm < 0, ϵa > 0 and the portion of the incident 
light wave vector that is parallel to the interface is of equal magnitude to ksp. By using light 
incident to the sensor at an angle θ, at which a small part of the light gives rise to an 
evanescent wave penetrating outside of the glass (see section 6.6.2), the wave vector 
parallel to the surface of the incident light is  𝑘) = R$ X𝜖Z 𝑠𝑖𝑛 𝜃  (6.8) 
where ϵg is the dielectric constant of the glass prism. During an SPR experiment, the angle 
of incidence is varied and at a certain angle, known as the resonance angle, kx is equal to 
ksp and surface plasmon resonance occurs, manifesting as a minimum in the reflected light 
intensity. Given that |ϵm| ≫ |ϵa|, equation (6.7) can be simplified to 𝑘?` = R$ X𝜖a and 
further to 𝑘?` = R$ 𝑛a where na is the refractive index of the ambient medium. Thus, shifts 
in the resonance angle can be used to probe, with high sensitivity, changes in refractive 
index close to the interface, for example due to adsorption of molecules or changes in the 
conformation of particles bound to the surface.  
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Figure 9. Schematic representation of the key theoretical principles behind surface plasmon resonance (SPR) 
using the Kretschmann configuration. ϵm is the real part of the dielectric function of the metal, ϵa and ϵg are 
the dielectric constants of the ambient medium and the glass, respectively. ksp and kx are the wave vectors of 
the plasmon and the horizontal component of the p-polarized light incident at an angle θ, causing total 
internal reflection and an evanescent wave. When kx = ksp resonance occurs, electrons at the gold-ambient 
interface oscillate coherently. ksp is dependent on the refractive index of the ambient medium, which can be 
measured as a function of a measurable decrease in the amount of reflected light at the critical angle. 
The SPR response R, upon molecular binding to the gold surface can be described using 
the expression 𝑅 = 𝑆(𝑛d − 𝑛a) f1 − 𝑒ijk l (6.9) 
where S is the sensitivity factor of the system, nf and na are the refractive indices of the 
bound film and the ambient medium, respectively, δ the decay length of the light intensity, 
and d corresponds to the thickness of the bound layer, e.g. the height of bound vesicles.[96, 
169] Simultaneously, the surface coverage Γ,	  in	  mass	  per	  surface	  area,	  is	  described	  by	  	  𝛤 = (no-nL)pn/p$ 𝑑 (6.10) 
where dn/dc is the derivative of the refractive index with respect to the molecular 
concentration in solution.[170] Together, equation (6.9) and (6.10) yield the expression  Γ = ps(pn p$⁄ )[T-vij k⁄ ] 𝑅, (6.11) which	  allows	  for	  calculation	  of	  the	  surface	  coverage	  Γ	  from	  the	  SPR	  response	  R.	  By probing 
with two wavelengths of light simultaneously (multiparametric SPR), the ratio of the SPR 
responses R can be expressed as 
xyzxy/ = syz(pn p$⁄ )yz{1−𝑒−
𝑑𝛿𝜆1~
sy/(pn p$⁄ )y/{1−𝑒− 𝑑𝛿𝜆2~ (6.12) 
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where λ1 and λ2 denote the two wavelengths of light used. This relation can be used to 
determine the thickness d of a bound layer. 
6.6   Light microscopy 
Methods capable of identifying and quantifying cellular responses are useful when 
assessing how particle properties affect key events in the immune response. In the context 
of vaccination key events include antigen uptake by an APC. Uptake processes can be 
characterized and quantified using microscopy and current high-resolution imaging 
methods provide opportunities to do so with precision. In particular, live-cell imaging 
allows us to observe the dynamics of such processes in real-time. In this chapter, a brief 
overview of the basics of optical microscopy, some specialized microscopy techniques and 
examples of how they have been used to study cellular uptake of different types of particles 
in sizes ranging from tens to a few hundred nm will be given. 
 
Convex lenses have been used for more than five hundred years to magnify objects beyond 
the human eye’s ability to observe and the invention of the microscope took place in the 
17th century.[171] Thanks to these advances, we have been able to visualize and 
understand microorganisms, our own cells and eventually also their constituents.  
 
There are many microscopy subtypes and setups but the basic construction of an optical 
microscope is mostly the same in all cases. In essence, light from a light source such as a 
lamp, LED or laser passes through a condenser (not necessarily when a laser is used) and 
then interacts with a specimen.[171] The light is collected by the objective, which contains 
one or several lenses and that helps focus the image of the specimen at the optical plane of 
an eyepiece or a camera.[171] In the simplest form of microscopy, brightfield, the light is 
simply transmitted through the specimen; all the light is collected and the contrast is given 
by the attenuation of the light due to the sample. However, many specimens have low 
contrast, making structures difficult to separate from the background. Therefore, there are 
variants of optical microscopy aimed at enhancing the contrast, such as darkfield, phase 
contrast, polarization microscopy and differential interference contrast (often referred to 
simply as DIC).[172-175] In addition to the contrast, the resolution is a critical parameter 
for how well small objects are visualized using light microscopy. The resolution limit is a 
constraint that the wavelike properties of light place on conventional light microscopy. 
When light from a point source passes through a circular aperture, such as a lens, it is 
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diffracted and will appear as a bright spot surrounded by a series of concentric circles (an 
Airy disk and Airy pattern).[176] When two objects come close together, their Airy 
patterns overlap and they cannot be visually separated. The work by Abbe, Rayleigh and 
Airy helped formulate the dependency of the resolution limit, d, on the wavelength of the 
light, λ, and the objective used for imaging:  𝑑 = T.EE%En	  PnC = T.EE%E  (6.13) 
where n is the refractive index of the medium, θ is the half angle subtended by the objective 
and NA is the numerical aperture of the objective.[176-178] For modern instruments, this 
means approximately half the wavelength of the light, in practice.  
 
An important component of many modern microscopy techniques is the use of fluorescent 
labels, such as antibodies conjugated to fluorophores (see section 6.1) or proteins which 
are expressed with the tag directly attached. This has been crucial not only to detect objects 
smaller than a couple hundred nanometers but also to visualize cellular structures and 
observe dynamic processes, such as uptake. Fluorescence has been instrumental in the 
development of the imaging field, both as a means to improve the contrast but additionally 
in allowing us to move beyond the diffraction limit using techniques such as confocal laser 
scanning microscopy and super-resolution imaging. 
6.6.1   Widefield fluorescence microscopy 
The simplest type of fluorescence microscopy is widefield fluorescence microscopy, or 
epifluorescence microscopy. In this technique, multichromatic light is sent through an 
optical excitation filter that allows only light of wavelengths suitable for excitation of a 
particular fluorophore to pass; the light meets the main dichromatic mirror, a component 
that selectively reflects or transmits light of different wavelengths. The dichromatic mirror 
reflects the short-wavelength excitation light through the objective and onto the specimen. 
The light emitted by fluorophores in the sample is collected by the objective and meets the 
main dichromatic mirror, which transmits this light that then passes through an emission 
filter that allows light of only certain wavelengths to pass to the eyepiece or camera (Figure 
10).[179] The excitation and emission filters together with the dichromatic mirror are 
generally mounted into a filter cube. It is common to have multiple filter cubes suitable for 
imaging different fluorophores. One can then switch from one to the other and image 
different labeled structures in sequence.[180] 
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Figure 10. General setup of a widefield fluorescence microscope, illustrating the light path from the light 
source, through excitation filter, dichromatic mirror and objective to the sample, where it excites a 
fluorophore that emits light of a different wavelength. The emitted light travels through the objective, 
dichromatic mirror and emission filter to the eyepiece or detector. 
Widefield fluorescence microscopy has been applied to study cellular uptake of different 
particles of interest. Van der Schaar et al. used widefield microscopy to study cellular 
uptake of DiD-labelled Dengue virus.[62] They elucidated both the clathrin-mediated 
internalization process and the endocytic trafficking of the virus through fluorescent 
labeling of endocytic machinery components.[62] Using HIV-1 virus-like particles, Endreß 
et al. showed two types of HIV-cell interactions: either the virus-like particle became 
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immobilized upon contact or there was a very short-lived dynamic interaction (in the range 
of 20-50 ms) followed by dissociation.[181] de Bruin et al. used epidermal growth factor to 
direct delivery of polyethylenimine polyplexes to cancer cells that overexpress epidermal 
growth factor receptor. Widefield microscopy revealed faster and more efficient 
internalization of epidermal growth factor receptor-targeted compared to untargeted 
polyplexes.[182] Furthermore, Tian et al. studied cellular uptake and processing of 
exosomes.[60] Single particle tracking was used to study the movement of exosomes in 
medium, on the cell surface and intracellularly in endosomes and lysosomes, identifying 
distinct movement patterns distinguishing membrane-bound from freely diffusing 
exosomes. Trypan blue was used to distinguish between intra- and extracellular DiI-
labelled exosomes. Octadecyl rhodamine B chloride-labelled exosomes were used to 
discern that exosomes were taken up through endocytosis and not fusion with the cell 
membrane.[60] 
 
A drawback of widefield fluorescence microscopy is that since all emitted light within a 
wavelength range is collected, there is usually a high background from out-of-focus 
fluorophores. Total internal reflection fluorescence (TIRF) microscopy and confocal laser 
scanning microscopy (CLSM) are two techniques that have been developed in order to 
address this issue. 
6.6.2   Total internal reflection fluorescence microscopy 
TIRF microscopy is a surface sensitive technique that relies on selectively exciting 
fluorophores using an illumination depth restricted to the area closest to an interface 
between two materials of different refractive indices, n1 and, n2. The fluorophores that are 
outside of the illuminated area remain unexcited and do not contribute to the background 
fluorescence. The materials of the interface are generally a sample, with low refractive 
index, e.g. water, on top of a glass coverslip, with high refractive index, as seen in Figure 
11.[183]  
 
	  	   54	  
 
Figure 11. Schematic of total internal reflection fluorescence (TIRF) microscopy. When incident light of 
angle θ1, greater than the critical angle θc, encounters an interface between a medium with high refractive 
index (n1, coverslip) and a medium with low refractive index (n2, sample), the light is totally internally 
reflected. This leads to the formation of an evanescent field that extends a small distance into the sample. 
Thus, only the fluorophores within this field emit fluorescence while fluorophores that are further away from 
the interface remain unexcited. 
How a light beam is refracted when passing through such an interface is described by 
Snell’s law: 𝑛T sin 𝜃T = 𝑛E sin 𝜃E (6.14) 
where θ1 is the angle of incident light and θ2 is the angle of refracted light. If the second 
material has a lower refractive index than the first (n1 > n2) and the angle of incidence is 
equal to what is termed the critical angle, θc, the refracted light will travel along the 
interface of the two materials. The critical angle is given by: 𝜃 = sin-T n/nz . (6.15) 
If the angle of incidence is larger than the critical angle (θ1 > θc), the light is totally internally 
reflected at the interface, giving rise to an evanescent field that extends a small distance 
into the second material.[183] The light intensity, I, decays exponentially with the distance 
from the interface, z, according to: 𝐼(𝑧) = 𝐼.e- p⁄  (6.16) 
where I0 is the intensity at the interface and d is the characteristic decay depth, defined as: 𝑑 = %1n/ S ?@A/C?@A/C − 1W-T E⁄  (6.17) 
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where λ is the wavelength of the incident light.[184] The surface-confined illumination 
eliminates background fluorescence, making TIRF microscopy a technique with high 
signal-to-noise ratio compared to widefield microscopy. 
 
TIRF microscopy has been used to study cellular uptake, for example by Schmidt et al., 
who studied pH-triggered fusion of vaccinia virions to HeLa cells using a microfluidic cell 
trap.[64] The viruses were labelled with a self-quenching concentration of octadecyl 
rhodamine B chloride and the virus cores were GFP-tagged. A reduction of the pH was 
used to induce fusion, which caused dequenching of the octadecyl rhodamine B chloride 
simultaneous to reduction of the GFP signal due to internalization of the virus core.[64] 
TIRF has also been used to visualize quantum dot diffusion on the surfaces of immune 
cells, with single particle tracking used to determine diffusion constants, followed by 
uptake quantified by measuring the overall decrease in fluorescence as the quantum dots 
disappeared from the field of view when taken up.[185] It was shown that the size and 
shape of the quantum dots influence both their final intracellular fate and their behavior 
on the cell membrane; more specifically, quantum dots with a high aspect ratio exhibited 
slower movement.[185] Furthermore, TIRF has been used to show the dynamics of 
cholesterol-modified Cy3-labelled siRNA internalization.[186] 
6.6.3   Confocal laser scanning microscopy 
CSLM is a popular technique that allows optical sectioning, which is achieved through the 
use of laser illumination, providing an intense and focused illumination spot, and a 
pinhole, an adjustable aperture in the conjugate focal plane.[187] The pinhole allows only 
light from the focal plane to pass, thus achieving optical sectioning, while additionally 
eliminating light from the Airy pattern of the illumination spot.[179] That the point spread 
function is reduced in this manner leads to an improvement in the lateral resolution dx,y: 𝑑, = ..1%  (6.18) 
where λ is the wavelength of light and NA is the numerical aperture of the objective 
used.[180] The image is formed by scanning the illumination over the specimen while 
recording the emitted intensity spot by spot (pixel by pixel) with a photomultiplier tube, 
which is ideal for detecting weak signals.[187] By axially moving the focal plane, image 
stacks can be collected in order to obtain three-dimensional information. Axially, the 
resolution limit dz is given by: 
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𝑑 = T.1%n/  (6.19) 
where n is the refractive index and the other parameters as previously defined.[180] 
 
CLSM is a useful technique when studying cellular uptake and trafficking, since optical 
sectioning can be used to provide three-dimensional information, something that is not 
obtainable with widefield microscopy. In continuation of van der Schaar’s work[62] 
mentioned in the widefield section, Chu et al. showed, using confocal microscopy, that 
interaction takes place between DiD-labelled Dengue virus and GFP-tagged 
autophagosomes during early Dengue infection.[63] CLSM has been widely used for 
studying uptake of liposomes for pharmacological applications both in vitro and in 
vivo.[188] There are essentially four ways by which liposomal content can be delivered: 
extracellular release of content following adsorption to the membrane, endocytosis, fusion 
of the liposomal and cell membranes and exchange of lipophilic compounds from the 
liposomal to the cell membrane.[188] By using fluorescent labeling in a strategic manner, 
confocal microscopy can be used to determine which mechanism is involved in a particular 
case. For example, by loading self-quenching concentrations of a dye inside the liposome 
and observing where dequenching occurs, it can be observed where the cargo is 
released.[188] Labeled lipids can be used to elucidate whether uptake takes place through 
fusion or through an endocytic pathway by observing co-localization with certain labeled 
cell membrane constituents.[188] 
6.7   Flow cytometry 
An important step of the immune response is the antigen presentation by DCs, which is a 
crucial step for activation of T cells. The amount of antigen presented on the DC surface 
in response to changes in the physicochemical properties of vaccine vectors can be assessed 
using flow cytometry. Indeed, flow cytometry is often used for characterization and 
quantification of cells and cell constituents. It is a popular technique in different fields of 
research and has a set of uses ranging from, for example, determination of cell viability to 
quantification of phagocytosis.[189, 190] In recent years, flow cytometry has, in addition 
to being an invaluable research tool, become an important diagnostic and prognostic tool 
in the clinical treatment of cancer and immunological diseases.[191] Furthermore, the use 
of flow cytometry has stretched beyond the analysis of cells to also include biologically 
relevant micro- and nanoparticles, such as exosomes.[192] 
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The large variety of applications and their increasing complexity aside, the flow cytometry 
technique relies, in essence, on three basic building blocks: 1) the arranging of the cells into 
a single file through a flow cell, 2) the optical system comprising one or several lasers 
generating the illumination of the sensing volume through which the cells pass, as well as 
a set of lenses and filters to focus and direct the light which is scattered and/or emitted by 
the cells, and 3) the electronics used to convert this light to an electronic signal. Due to the 
different components comprising a flow cytometer, one might say that there is not a 
singular origin of the technique, but rather several advancing paths converging into the 
development of cell microfluorometry by van Dilla et al. in 1965.[193] This chapter will 
give a brief overview of the theory behind flow cytometry, describing a typical instrument 
and the physical phenomena it employs.  
6.7.1   Principles and instrument design 
As previously touched upon, a flow cytometer can be said to consist of three main 
components: a microfluidic system, an optical system and an electronic system that 
function in a synchronized manner (Figure 12).[194] In this section, each of these systems 
is presented in some detail. 
6.7.1.1   Microfluidics 
The role of the microfluidic system is to ensure that the cells pass in a controlled manner 
one by one through the sensing volume, or interrogation point as it is sometimes referred 
to. This is crucial to maintain uniform and reproducible illumination conditions. The 
arrangement of cells into “a single file” is achieved through hydrodynamic focusing by use 
of a sheath flow. A pressurized stream of sheath fluid is maintained into which the sample 
is injected at a higher pressure, causing a difference in flow speeds between the two fluids 
that maintains the cells in the central stream, the “core”. A strategic narrowing of the flow 
cell causes a simultaneous increase of the flow speed and a decrease of the core cross-
section to the point where cells generally pass through the sensing volume one by one.[195] 
Generally speaking, it is crucial to maintain laminar flow by avoiding e.g. too acute 
narrowing of the flow cell and sharp edges in the design as well as blockages and air bubbles 
during operation. The nature of the flow in a tube is determined by four parameters, whose 
relationship is often expressed by the dimensionless Reynolds number, Re:  𝑅𝑒 = p8  (6.20) 
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where v [m/s] is the average velocity throughout the cross-section of the tube, d [m] is the 
tube diameter, ρ [kg/m3] and h [kg/sm] is the fluid density and viscosity, respectively. At 
Re greater than 2,300 the laminar flow starts to break down in favour of turbulence.[196] 
The sensing volume is generally located in an area with “slug flow”, characterized by 
constant flow speed across the diameter of the core, a result of the aforementioned 
narrowing of the flow cell. This is advantageous as it minimizes the velocity differences 
between cells at different distances from the centre of the core compared to the parabolic 
flow profile of a laminar flow that arises from the no-slip boundary condition.[195]  
6.7.1.2   Optics 
When cells pass through the sensing volume, i.e. the laser beam, the light that is scattered, 
and emitted in the case of fluorescently labeled cells, gives information about their 
properties. Physically speaking, scattered light consists of light that has been diffracted, 
reflected, refracted, anomalously diffracted and Rayleigh scattered.[196] Maxwell’s 
equations can be solved to describe the propagation of light after it has been scattered by 
an object. In the case of a cell, there are many intracellular objects with varying properties, 
and the morphological and biochemical complexity of a cell thus make the mathematical 
description of this process challenging even though it has been attempted.[197-201] Such 
modeling is however not standard in flow cytometry, where the light scattering properties 
of cells are measured and related to two main properties. Light that is deflected around the 
edges of the cells, parallel to the direction of the laser beam, is termed forward scatter (FSC) 
and gives information about the size of the cells. Light that is scattered perpendicularly to 
the laser beam is termed side scatter (SSC). Side-scattered light is primarily scattered from 
intracellular structures, therefore giving information about the internal complexity.[190] 
The intensity of the SSC is proportional to what is often termed cell granularity.  
 
In addition to the information from the scattered light, which is obtained label-free, 
features of interest can be tagged with fluorescent labels (see section 6.1). Fluorescent 
probes are utilized in order to detect and quantify the amount of for example nucleic acids, 
proteins or to assess cell viability.[190] Since different fluorophores have different emission 
and excitation spectra, a cell can be stained with several probes with different fluorophores 
(fluorochromes). The most common fluorophores used for flow cytometry include 
fluorescein isothiocyanate (excitation/emission 495/520 nm), phycoerythrin 
(excitation/emission 565/578 nm) and allophycocyanin (excitation/emission 650/660 
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nm).[190] Once excited by lasers with light of suitable wavelengths, monochromatic 
mirrors and optical filters are used to guide emitted light from different fluorochromes in 
different “channels” to different detectors.[195] 
6.7.1.3   Electronics 
The electronic system in a flow cytometer consists of a series of detectors that convert the 
scattered and emitted light into electrical currents that can be recorded and visualized. 
There are generally two types of detectors used: photodiodes and photomultiplier tubes. 
Photodiodes are typically used for the FSC, which has a high intensity, while 
photomultiplier tubes are used to amplify and detect SSC and emitted light.[202] In both 
cases, the output signal is proportional to the incoming number of photons.[190] 
 
 
Figure 12. (A) A schematic representation of a flow cytometer. The microfluidic system arranges the cells 
into a single file through the beam of one of several differently colored lasers, i.e. the sensing volume, (B). 
The light that is scattered parallel to the laser beam, termed forward scatter (FSC), provides information 
about the size of the cells and the light that is scattered perpendicularly, termed side scatter (SSC), gives 
information about the internal complexity of the cells.  Dichromatic mirrors and optical filters are used to 
guide the SSC and light emitted from fluorescent labels to different photomultiplier tubes (PMTs). 
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6.7.2   Data analysis 
In flow cytometry many parameters are usually measured on numerous individual cells, 
which means that a large and important part of the method comprises the processing of the 
data. Common ways to display the data include dot plots, which visualize the magnitude 
of two parameters at the same time, and histograms, which visualize the number of cells 
and to which degree they are, for example, expressing a marker of interest.  
6.7.2.1   Spectral compensation 
Spectral (or colour) compensation is a standard procedure used when several 
fluorochromes are used in one measurement. Overlap of the emission spectra of the 
fluorophores means that light from several fluorochromes can pass through the emission 
filters and be detected in the same channel. Spectral compensation is thus needed to adjust 
for the light each fluorochrome contributes with in channels other than its own, and is 
done by measuring each fluorochrome alone and calculating how much of the total light 
each contribute with to the different channels.[190] This information is then used to 
compensate for any overlap in the subsequent measurement.[203] 
6.7.2.2   Gating 
Gating is a process commonly used to eliminate results from debris and dead cells and to 
subsequently enumerate cells with certain properties.[190] Cells are visualized in a two-
dimensional scatter plot in which the user defines one or several regions, restricting further 
analysis to certain subsets of cells. By in this manner iteratively visualizing and zooming 
in on cells with a certain set of markers, identification and quantification of cell 
subpopulations is performed.[204] 
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7  	  
Results 
The general scope of this thesis work has been to gain fundamental understanding of how 
the physicochemical properties of lipid nanoparticles used as mucosal vaccine carriers 
influence the development of protective immunity and to reveal the properties that are 
decisive for effective vaccine delivery. Such knowledge will, without doubt, help 
rationalizing the process of designing vaccine formulations. This goal requires 
characterization of both the vaccine particles and the biological response they elicit, and in 
this work, we have made an attempt to undertake both. We have addressed the biological 
response to antigen-carrying lipid particles using model systems of varying levels of 
complexity, ranging from an in vivo immunization model to simpler, yet informative, in 
vitro models. As for particle characterization, we have identified a need for protocols for 
physicochemical characterization of nanoparticles relevant in this context; it has been our 
goal to contribute to the field by developing methods to characterize the stiffness and 
optical properties of small vesicles. 
 
In this chapter, I provide brief summaries of key findings of the appended papers, as well 
as some additional experimental results of relevance for the scope of the thesis work. In 
Paper I, we performed a detailed characterization of the immunogenicity of two types of 
antigen-carrying liposomes in an in vivo mouse model and identified that the liposome 
formulation most capable of efficiently inducing a local CD4+ T cell response was also the 
most protective against disease. In Paper II, we therefore focused on optimizing T cell 
priming ability by studying antigen presentation by, and activation of, dendritic cells in 
vitro. During that particular work, we discovered that gel-phase liposomes were more 
immunogenic vaccine carriers than those with fluid phase membranes. In an attempt to 
better understand the mechanisms underlying this effect, we studied uptake of gel and fluid 
phase liposomes in Paper III. As an extension, we present additional experimental results 
from an exploration of single-cell-and-particle imaging for the investigation of the 
interaction between vaccine carriers and the outer cell membrane of dendritic cells. 
Additionally, we also present further investigations of the immunogenicity of formulations 
investigated in Paper II and III. As for particle characterization, in Paper IV, we used SPR 
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in combination with cell membrane mimics to characterize liposome deformation induced 
upon specific ligand-receptor pairing between the liposome and cell-membrane mimic. 
Different degrees of deformation and binding valency were observed for gel and fluid phase 
liposomes, which might be of relevance for differences observed in cellular uptake. Finally, 
in Paper V, we present how a newly developed waveguide-based microscopy setup can be 
used to characterize biological nanoparticles modified with a dye that shares similarities to 
the one used to visualize cellular uptake in Paper III. 
7.1   Paper I 
In Paper I, we aimed at combining the universal influenza A vaccine candidate CTA1-
3M2e-DD with liposomes into an effective mucosal vaccine formulation. CTA1-3M2e-
DD is a fusion protein that combines the mucosal adjuvant CTA1-DD with the 
ectodomain of influenza matrix protein 2 (M2e), which is highly conserved in all human 
influenza A virus strains. In addition to three repeats of M2e, the fusion protein consists of 
the enzymatically active cholera toxin A1 subunit (CTA1), which has an 
immunomodulating effect, and a dimer of the D-fragment from Staphylococcus aureus 
protein A (DD): an effective DC targeting moiety. In this work, the fusion protein was 
formulated into two types of POPC-based liposomes: non-PEGylated, where fusion 
protein was covalently attached directly to functionalized lipid headgroups, and 
PEGylated, where it was attached at the ends of PEG(2000) spacers (Figure 13).  
 
Figure 13. Schematic of the non-PEGylated and PEGylated vaccine vectors used in Paper I. The liposomes 
where 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)-based and contained 10% cholesterol. The 
fusion protein was encapsulated and covalently attached using thiol-maleimide chemistry, either directly to 
lipid headgroups (non-PEGylated) or to the ends of PEG(2000) spacers (PEGylated). 
The liposomes were characterized with respect to size, morphology, protein load and 
surface charge. The main differences between the two formulations, in terms of 
physicochemical characteristics, besides the PEGylation, were a difference in zeta 
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potential, the non-PEGylated liposomes being more negatively charged, and protein load; 
the PEGylated carried approximately 30-40% more proteins. 
 
A thorough in vivo investigation of the immunogenicity of fusion protein-carrying 
liposomes compared to free fusion protein revealed several interesting differences. Upon 
intranasal immunization, the non-PEGylated vector lead to significant protection from a 
lethal challenge with a live heterosubtypic influenza virus (a virus of a different strain than 
the M2e originated from), while naïve mice as well as mice immunized with free fusion 
protein or PEGylated vectors all succumbed to infection. Non-PEGylated liposomes and 
free fusion protein induced comparable systemic immune responses, giving rise to higher 
levels of IFN-γ and serum IgG than the PEGylated liposomes. When investigating the 
local immune response in the lung, however, it was discovered that the non-PEGylated 
vector more strongly induced an M2e-specific CD4+ T cell-response as well as higher local 
secretion of IgA than both the free fusion protein and the PEGylated vector. We further 
investigated the role of the of M2e-specific CD4+ T cells; following their depletion in mice 
immunized with the non-PEGylated vector prior to virus challenge, the survival was 
reduced to 0 %. Thus, the crucial role of cell-mediated immunity for protection was 
confirmed. Interestingly, while investigating the T cell priming ability, we found that free 
fusion protein induced strong proliferation of specific CD4+ T cells earlier after 
immunization than the non-PEGylated vaccine vector. Thus, it appears that the liposome-
assisted delivery delays T cell priming but, in the end, leads to a stronger, more effective T 
cell response. Additionally, we found that the liposomes gave significant IgG titres already 
after two immunizations, while the free fusion protein required three. This indicates an 
opportunity for using liposome-assisted delivery to reduce the need for booster 
immunizations.  
 
In Paper I, we found that immunization with non-PEGylated vaccine vectors better 
protected from a lethal influenza virus infection than both free fusion protein and the 
PEGylated vaccine vector. Furthermore, we found that the protective effect correlated with 
increased activation of the local immune response in the lung. Specifically, we observed 
slower, but ultimately stronger, proliferation of CD4+ T cells, which proved crucial for the 
protective effect. Taken together, these results highlight both the importance of inducing 
local, cell-mediated immunity and the promise of using liposome carriers to improve the 
immunogenicity of the CTA1-3M2e-DD fusion protein.  
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7.2   Paper II 
In Paper I, cell-mediated immunity proved crucial for the observed protective effect of the 
non-PEGylated vaccine vector. Priming of CD4+ T cells requires presentation of peptides 
on cell surface-associated MHC II by DCs (see section 2.2 and 2.3); indeed, the duration 
and magnitude of such antigen presentation determines the degree and quality of antigen-
specific T cell activation.[205, 206] Thus, we chose to focus our investigation in Paper II 
on how the antigen presentation by DCs is affected by chosen physicochemical properties 
of vaccine carriers, while simultaneously screening for promising vaccine carrier 
candidates. In order to observe the kinetics of the antigen presentation, the amount of 
functionally presented antigen on the DC surface was monitored at various time points 
after administration of different formulations. The quantification of the antigen 
presentation was performed using flow cytometry and immunostaining with the YAe 
antibody, which recognizes the Eα peptide when presented in the MHC II. Therefore, the 
antigen portion of the CTA1-DD-based fusion protein used in this study consisted of the 
Eα peptide. With the results from Paper I as a starting point, we attempted to 
systematically vary physicochemical properties of fusion protein-carrying lipid particles. 
 
Firstly, PEGylated and non-PEGylated POPC-based liposomes were formulated with 
fusion protein both encapsulated and surface-bound, as in Paper I. During the work 
presented in Paper I, it proved difficult to tightly control the portion of encapsulated fusion 
protein. Thus, secondly, the amount of surface-bound protein on non-PEGylated POPC-
based liposomes was varied in an attempt to investigate the influence of protein load 
independently from PEGylation and percentage encapsulated protein. Two different 
formulations with approximately three times difference in protein load were produced. 
Lastly, to assess the influence of shape and size, DSPC-based lipodisks, i.e. flat bilayer 
circles stabilized by their high PEG content,[56] as well as liposomes of a similar 
composition (abbreviated DSPC-PEG-FP) for direct comparison were produced. The 
lipodisks were 22 nm in diameter, while the DSPC-PEG were on average 110 nm in 
hydrodynamic diameter. Out of all the formulations tested, only the DSPC-PEG-FP 
liposomes, which were in gel phase as opposed to the fluid phase POPC-formulations, led 
to a substantial increase in presented antigen compared to free fusion protein. For this 
reason, we decided to more closely investigate the influence of membrane phase state on 
antigen presentation by focusing on liposome formulations primarily consisting of either 
gel phase DSPC or fluid phase 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) (Figure 
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14A). The influence of DOPC-PEG and DSPC-PEG liposomes, both with coupled fusion 
protein (DOPC-PEG-FP and DSPC-PEG-FP; Figure 14B) and when co-administered with 
the fusion protein (DOPC-PEG +FP and DSPC-PEG + FP; Figure 14B), on antigen 
presentation by DCs was investigated. After 24 hours of incubation, DOPC-based 
liposomes did not significantly improve antigen presentation compared to free fusion 
protein (Figure 14C). Meanwhile, DSPC-PEG-FP increased the amount of presented 
antigen by a factor of approximately 8 and DSPC-PEG + FP by a factor of approximately 
4 compared to free fusion protein. Interestingly, it was also observed that the increase in 
peptide presentation induced by the DSPC-based formulations was accompanied by an 
increase in surface-bound MHC II; however, the YAe fluorescence intensity increase was 
greater, indicating an improved peptide loading efficiency of DSPC-PEG-FP, and to a 
smaller extent also DSPC-PEG + FP, compared to the other formulations.  
 
Figure 14. (A) Molecular structures of the main lipids used in the investigation of the influence of membrane 
phase in Paper II: 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-distearoyl-sn-glycero-3-
phosphocholine (DSPC). These phospholipids are identical with regards to their headgroup and length of 
their fatty acids, but DOPC has one unsaturation in each acyl chain, causing DOPC-based membranes to be 
in a fluid phase state while membranes out of the fully saturated DSPC are in a gel phase state at physiological 
temperature. (B) Schematic representations of the main liposome formulations used: PEGylated DOPC- and 
DSPC-based liposomes with fusion protein covalently coupled to maleimide at the end of the PEG(2000)-
chains (DOPC-PEG-FP and DSPC-PEG-FP), or given alongside the fusion protein (DOPC-PEG + FP and 
DSPC-PEG + FP). (C) YAe median fluorescence intensity (MFI) of D1 cells after 24 hours incubation with 
the various vaccine formulations. Error bars show standard error of the mean. Statistical significance: *p < 
0.05, ***p < 0.001. 
Additionally, the activation of the DCs, along with their co-stimulatory potential was 
investigated. Specifically, quantification of the membrane-bound co-stimulatory receptors 
and activation markers CD80 and CD86 was done by flow cytometry and release of the 
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relevant cytokines IL-1β	  (activates	  T	  cells,	  B	  cells	  and	  macrophages[11])	  and IL-6 (induces 
T and B cell activation and proliferation and increases antibody production[11]), was 
measured by ELISA. Overall, the DSPC-based fusion protein formulations were superior 
at activating DCs and inducing co-stimulation and cytokine release compared to both 
DOPC-based liposomes and free fusion protein. Additionally, coupling of the fusion 
protein to the DSPC-based liposomes proved beneficial for improving cytokine release. 
Meanwhile, liposomes administered without fusion protein proved poorly immunogenic. 
Taken together, the results in Paper II showed that DSPC-based liposomes are a promising 
adjuvant for the CTA-DD fusion protein system, improving antigen processing and 
presentation as well as co-stimulation, especially when used as a carrier particle.  
 
The observations in Paper II raised questions about what the underlying mechanisms of 
the efficacy of DSPC-PEG-FP may be. Firstly, increased uptake of this formulation, 
potentially caused by its lower deformability compared to the others, may be one reason; 
this possibility was explored in Paper III. Secondly, the ability of DOPC- and DSPC-
liposomes to provide opportunity for multivalent attachment, which is important in many 
processes, including various types of immune recognition, induction of uptake processes, 
etc. may differ.[207, 208] Thus, a method to explore differences in multivalent attachment, 
as well as liposome deformation, was developed in Paper IV.  
7.3   Paper III 
In Paper II, it was suggested that a difference in carrier internalization may have 
contributed to the observed differences in antigen presentation triggered by DOPC- and 
DSPC-based vectors. The literature suggests that soft, deformable particles are more likely 
to get trapped at the cell surface since their envelopment by the cell membrane is 
energetically more demanding.[135-137] We therefore hypothesized that the DSPC-
liposomes were more effective vaccine vectors because they were more readily internalized 
than their fluid-phase DOPC-based counterparts. Thus, in Paper III, we developed an 
experimental approach aiming at distinguishing between internalized and surface-bound 
liposomes. The chosen approach relies on labelling liposomes with the dye DiO. This dye 
inserts into the lipid membrane with the fluorophore facing outwards (Figure 15A), which 
in turn allows for quenching of the fluorescence emission with the membrane-impermeable 
molecule trypan blue (TB). For CLSM imaging as well as to investigate potential effects of 
the dye on cellular uptake, rhodamine-labelled liposomes, made by inclusion of a small 
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percentage of rhodamine-labelled lipids when producing the liposomes, were also used 
(Figure 15A). 
 
Figure 15. (A) Schematic representation of the fusion protein-carrying liposomes and labelling strategies 
used in Paper III: post-formation labelling with DiOC18(3) (3,3'-Dioctadecyloxacarbocyanine Perchlorate 
(DiO) and inclusion of a small percentage of rhodamine-labelled 1,2-Dihexadecanoyl-sn-Glycero-3-
Phosphoethanolamine (DHPE) lipid. DiO inserts into the lipid membrane with the fluorescent group facing 
outwards, allowing quenching of extracellularly bound liposomes with trypan blue (TB). (B) Median 
fluorescence intensity, measured by flow cytometry, of intracellular DiO in JAWSII cells incubated with 
labelled fluid and gel phase liposomes with (DO-FP-DiO and DS-FP-DiO) and without (DO-DiO and DS-
DiO) coupled CTA1-3α-DD fusion protein. Error bars show standard deviation. (C) Median fluorescence 
intensity of rhodamine associated to JAWSII cells incubated with labelled fluid and gel phase liposomes with 
coupled fusion protein (DO-Rho-FP and DS-Rho-FP) and without (DO-Rho and DS-Rho), measured by 
flow cytometry. (D) Confocal laser scanning microscopy (CLSM) images after 24 hours of incubation with 
the indicated formulations. 
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When setting out to quantitatively compare fluorescence emission of the two liposome 
types, we were cautioned by unpublished work by Lubart et al.[67], which specifically 
observed differences in dye insertion between gel and fluid phase membranes. For this 
reason, thorough characterization of fluorescence emission was performed and used for 
normalization of flow cytometry data. In accordance with the findings by Lubart et al., we 
observed poorer insertion in DSPC-based membranes compared to DOPC-based ones; 
additionally, and somewhat surprisingly, we observed that the presence of coupled fusion 
protein on the liposomes had an even greater limiting effect on fluorescence emission. 
These findings emphasize the importance of mindful use of fluorescent labelling and calls 
for the further characterization of the liposomes and their labelling. Advanced analytical 
techniques capable of correlating fluorescence emission with other features, such as size 
and scattering properties, will be crucial analytical approaches in this regard. We present, 
in Paper V, a technique capable of doing just that, with single nanoparticle resolution. 
 
To study uptake, cells of the DC cell line JAWSII were incubated with DiO-labelled fluid 
and gel phase liposomes with and without coupled CTA1-3Eα-DD fusion protein (DO-
FP-DiO and DS-FP-DiO; and DO-DiO and DS-DiO, respectively) for various lengths of 
time up to 24 h, keeping the lipid concentration constant. Flow cytometry analysis revealed 
steady internalization of the DO-FP-DiO-liposomes, whereas DS-FP-DiO was mainly 
internalized between 4 and 24 h (Figure 15B). At 24 h, almost the same amount of DS-FP-
DiO had been internalized as DO-FP-DiO. Both liposome types, when given without 
fusion protein, were poorly internalized, indicating that the targeting functionality of the 
fusion protein was required for effective liposome internalization. Quenching with TB, 
showed that >80 % of liposomes where internalized at all time points and that there were 
no noteworthy differences between formulations. This is true with the exception of DS-
DiO, which was more poorly internalized in the early timepoints. When instead using 
rhodamine-labelled liposomes, the uptake behaviour was qualitatively very similar (Figure 
15C). 
 
To obtain a more detailed view of the uptake process of rhodamine-labelled liposomes, 
CLSM imaging was performed. A qualitatively similar kinetic behaviour was observed as 
with flow cytometry. Additionally, DO-Rho-FP was observed to accumulate on the cell 
membrane at the early timepoints, followed by efficient internalization. The initial 
membrane binding was not observed to a significant extent for the other three 
	  	   69	  
formulations. This may indicate that distinct uptake pathways are at play. Furthermore, 
the DSPC-based liposomes were observed to form aggregates with time, accumulating in 
cloud-like formations at the outer surface of the cells (Figure 15D). This effect appeared to 
be dependent on the presence of cells, not just exposure to cell culture medium. 
Furthermore, the aggregates were removed by the same washing protocol used before flow 
cytometry analysis, indicating the that the majority of the fluorescence signal in Figure 
15C originated intracellularly, as with the DiO-labelled liposomes. Undoubtedly, though, 
the DSPC-liposome aggregation may have contributed to the distinct kinetics observed for 
DS-Rho-FP. Interestingly, delayed internalization of gel phase vaccine carriers, correlating 
with improved immunogenicity of the formulation, has been observed in vivo and was 
attributed to depot formation of the gel phase liposomes.[132] Thus, the aggregation 
behaviour observed in the DSPC-based liposomes may potentially be beneficial as a means 
to achieve prolonged release.  
 
It appears that the softer fluid phase liposomes did not, as suggested by literature and 
initially hypothesized by us, appear to get trapped at the cell surface. Rather, the opposite 
was observed: DO-FP-DiO and DO-Rho-FP were initially internalized at a faster rate than 
their DSPC-based counterparts. Thus, although this study was carried out on a different 
DC cell line than that used in Paper II, the data suggest that a difference in uptake efficiency 
might not be the main reason behind the differences in antigen presentation observed in 
Paper II, where DSPC-based vectors increased antigen presentation already before 4 hours 
of incubation. This, along with differences in how the different liposomes appear to bind 
to the cell surface, taken together with the differences in peptide loading into MHC II 
observed in Paper II, indicate that differences in uptake route, and potentially a resulting 
difference in intracellular fate, may be explanations for our observations. This calls for 
future investigations of the uptake pathways involved as well as of intracellular trafficking 
and fate.  
7.4   Additional experimental results: Further immunogenicity characterization 
of DOPC- and DSPC-based vaccine vectors 
Intrigued by the results in Paper II and III, we further investigated the immunostimulatory 
effect of the DOPC- and DSPC-based vaccine vectors. Our intention was to gain insights 
into whether there was a correlation between the significant increase in activation and 
antigen presentation in targeted DCs as observed in vitro (Paper II) and an enhanced 
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immune protective effect in vivo. For these experiments we used the same immunization 
protocol as in Paper I; accordingly, mice were intranasally immunized with CTA1-3M2e-
DD fusion protein, either free or coupled to DOPC- or DSPC-liposomes, or PBS as a 
negative control. This was followed by a homo- (X47; Figure 16A-B) or heterosubtypical 
(PR8; Figure 16C-D) live virus challenge, after which mortality and morbidity were 
monitored. The results with both virus strains were similar and survival (Figure 16, left 
panels) and weight loss (Figure 16, right panels) indicated immune protection as compared 
to the negative control. Most importantly, the liposome-coupled fusion protein provided 
better protection than free fusion protein, but no difference between the two liposome 
formulations was observed. The heterosubtypic challenge proved more severe, as expected, 
with fewer surviving animals and more dramatic weight loss. 
 
Figure 16. Intranasal immunizations of Balb/c mice were followed by challenge with either the 
homosubtypic x47 (A-B) or the heterosubtypic PR8 (C-D) virus strain. Survival (left panels) and weight loss 
(right panels) were monitored over time. 
Considering the previously observed difference between DOPC- and DSPC-based carriers 
in vitro, the lack of a differential effect in vivo was somewhat unexpected. In an attempt to 
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shed light on possible explanations for this observation, we examined the release of a wider 
range of cytokines with ELISA (Figure 17), using the same in vitro model system and 
method as described in Paper II. The cytokines investigated in this manner were IL-22, IL-
23, IL-27 and IL-10. IL-22 and IL-23 are greatly involved in maintenance and defence of 
mucosal barriers.[36, 39] IL-22 was found to be increased by free fusion protein, DOPC-
PEG-FP and DSPC-PEG-FP alike, while DSPC-PEG-FP increased IL-23 compared to the 
unstimulated control. IL-27, which drives regulatory T cells of the Tr1 subtype and has an 
inhibitory effect on Th1, Th2 and Th17 subset functions mediated by IL-10 production,[40] 
was most strongly expressed after activation with DSPC-PEG-FP. IL-10 is a major 
regulatory cytokine,[41] and increased release by DSPC-PEG-FP-activated cells compared 
to the other formulations could imply reduced protective effector functions. It is not, as 
such, surprising that vector rigidity would have the capacity to modulate the immune 
response. Indeed, it has previously been observed that rigid liposomes preferentially induce 
a Th1-type immune response, while fluid phase liposomes induced a Th2-type response in 
an in vivo leishmaniasis vaccine model.[130] However, the increased release of IL-27 and 
IL-10, indicating immune-suppressive effects of DSPC-PEG-FP, is surprising considering 
the promising results in Paper II and that it performs equally well as DOPC-PEG-FP and 
better than free fusion protein in vivo (Figure 16). It should be noted that, since the general 
trend among all measured cytokines is that they are increased by DSPC-PEG-FP, the net-
result may be a reduction of the effector functions due to regulatory cytokines, such as IL-
10. Nevertheless, taken together, the additional cytokine data may indicate that altering 
the physicochemical properties of vaccine vectors may have diverse and difficult-to-predict 
effects. However, the results with DSPC-based formulations convey optimism as improved 
immune protection with preserved mucosal barrier functions can be achieved. To what 
extent mucosal vaccination using DSPC-carriers can have immune-suppressive effects and 
be used for vaccines against autoimmune diseases warrants further investigations. It does, 
however, appear that the membrane phase state of liposomes can influence the polarization 
of the DC response, an aspect which should be further investigated.  
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Figure 17. Enzyme-linked immunosorbent assay (ELISA) was used to quantify the amount of (A) IL-22, (B) 
IL-23, (C) IL-27 and (D) IL-10 in DC cell line culture supernatants following activation for 24 h with 
PEGylated DOPC- and DSPC-based liposomes with CTA-1-3Eα-DD fusion protein covalently coupled to 
maleimide at the end of the PEG(2000)-chains (DOPC-PEG-FP and DSPC-PEG-FP), or given alongside 
the fusion protein (DOPC-PEG + FP and DSPC-PEG + FP), or free fusion protein (FP).  
Importantly, DC activation (as investigated in Paper II) is only one element of several that 
can impact the immunogenicity of an antigen. There are indeed many intermediate steps 
before the vaccine even reaches the DC and little is known about how, for example, the 
interaction of liposomes with different kinds of biological fluids, tissues and cells can affect 
their physicochemical properties. It has been shown that, when using identical liposomes, 
different administration routes have profound effects on vaccination outcomes,[209] A 
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possible reason for such effects might be changes to the vector properties depending on the 
specific microenvironment; an illustrative example of this is the aggregation that DSPC-
based liposomes underwent when subjected to biological fluids in Paper III. Thus, such 
reductionist in vitro models as the ones used in Paper II and III are useful for furthering 
detailed mechanistic understanding but fail to properly emulate the complex, multi-step 
process of mucosal vaccine delivery and therefore, at this point, to predict in vivo efficacy. 
A move towards using a sequential combination of in vitro assays would likely be useful 
for improving the understanding of the impact of different micro-milieus on particle 
properties and processes such as cellular uptake, activation, etc. However, such assays need 
to be accompanied by in vivo investigations to understand the relative impact of each 
element or step on vaccination outcomes to better design future liposome vectors for 
mucosal vaccination.  
7.5   Additional experimental results: TIRF microscopy-based study of cell-
particle interactions 
As concluded in Paper III, there is likely a difference in how DOPC- and DSPC-based 
vaccine vectors are internalized. It is, as yet, unknown how the initial interaction between 
cell surface and vaccine carrier influences initiation and progression of uptake and how 
that in turn affects the downstream processing of the antigen. For this reason, we aimed to 
develop a method that allows us to visually, in detail, probe interactions between lipid 
vaccine particles and cells on a single-particle and single-cell level. 
 
Visualizing movements of single particles requires a high signal-to-noise ratio and high 
spatial and temporal resolution. To fulfil these requirements, TIRF microscopy was used 
to visualize the movements of individual particles on the basal cell membrane and to 
analyse their trajectories. Additionally, we used a topographically patterned substrate with 
micropillars (Figure 18) to facilitate access to the basal membrane and more uninhibited 
movement compared to flat glass. As a proof of concept, a mouse-derived foetal skin 
dendritic cell (FSDC) line[210] was used, as robustness and ease of handling was a priority 
during the initial development.  
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Figure 18. Foetal skin dendritic cells (FSDCs) were cultured on a micropatterned glass substrate with pillars, 
made as follows: a chromium etching mask was transferred to the substrate by conventional 
photolithography and lift-off. The pillars were etched in the glass using reactive ion etching. The pillars were 
400 nm high and with 1 µm width and spacing, providing relative freedom of movement for lipid particles to 
interact with the basal cell membrane. The movements of the particles were observed using the surface 
sensitive technique total internal reflection fluorescence (TIRF) microscopy, which selectively illuminates 
the volume closest to the glass substrate. Single particle tracking was used to analyse the particle trajectories. 
Initially, two different micropatterns were tried: the pillars were 400 nm high and their 
width and spacing were kept the same at either 1 µm or 2 µm. FSDCs were cultured on flat 
glass and the two kinds of topographically patterned substrates. The cells were fixed, 
permeabilized and stained with DAPI and rhodamine phalloidin (labelling nucleus and F-
actin, a cytoskeleton marker, respectively). The morphology of the cells was inspected 
using epifluorescence microscopy. Since these cells are normally cultured on flat 
substrates, the flat glass sample was considered the positive control (Figure	  19A). Here, 
cells were seen to stretch out, forming thin filaments to outstretched attachment points. A 
similar morphology was seen on the 1µm pattern (Figure	  19B), while on the 2 µm pattern 
cells appeared more rounded and with fewer outreaching filaments (Figure	  19C). Since 
the cells exhibited normal morphology on the 1 µm pattern, this was chosen for use in the 
assay. 
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Figure 19. Foetal skin dendritic cells (FSDCs) stained with DAPI (nucleus, blue) and rhodamine phalloidin 
(F-actin, red), cultured on: (A) flat glass, or glass with 400 nm high pillars with either (B) 1 µm width and 
spacing or (C) 2 µm diameter and spacing. 
In order to study the interaction between lipid particles and cells, FSDCs were incubated 
with rhodamine-labelled fusion protein-functionalized liposomes (Figure	  20A). The cell 
membrane was labelled with PKH67 in order to visualize the cells (Figure	  20B). The 
imaging was performed at the level of the top of the pillars, by focusing on the thin layer 
of chromium deposited there in the manufacturing process. The field of view is the same 
in Figure	  20A and B; thus, the movement of the individual particles tracked using single 
particle tracking in Figure	   20C is taking place on the cell surface. Time-lapses were 
recorded at a speed of 5 frames per second. No particles showed the random movement 
patterns associated with free diffusion. Over short time scales, particles exhibited confined 
movement (see inset in Figure	   20C). Over time scales of several minutes, directed 
movement patterns could be observed (see main image in Figure	  20C). It was however 
difficult to determine if these were decoupled from movement of the cell itself. Particles 
were occasionally observed to flicker in and out of the focal volume, which could be 
explained by the fact that the normal morphology of DCs is not smooth: they generally 
have a multitude of protrusions (dendrites) that range from being filamentous to being 
more skirt-like depending on the level of activation.[211] Thus, it can be expected for 
particles to exhibit considerable movement also in the z-direction. 
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Figure 20. (A) Total internal reflection fluorescence (TIRF) micrograph of rhodamine-labelled fusion 
protein-functionalized liposomes (same formulation as the non-PEGylated vectors in Paper I) attached to 
the surface of the PKH67-labelled foetal skin dendritic cell (FSDC) seen in (B). (C) Trajectories over time of 
the liposomes in (A). Inset shows detailed track. The particles were tracked using a dedicated MATLAB 
script created within the division of Biological Physics, Chalmers University of Technology (available upon 
request).  
In conclusion, we have developed a tool that enables study of the interaction between 
vaccine carriers and the cell surface, which is the first step in the uptake process. From the 
particle trajectories, it is possible to calculate diffusion rates, which could give indications 
about differences in the valency of the attachment. Due to the dynamic and complex nature 
of the cell membrane, simplified models are needed to obtain detailed understanding of the 
impact of valency on particle binding. For this reason, in Paper IV, we developed a method 
that enables the study of binding valency and particle deformation using SPR and well-
defined cell membrane mimics. Combining the type of information obtainable with these 
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assays, we could characterize how changes to the particle properties influence the observed 
membrane interactions in a quantitative fashion. Correlation of such information with 
observed differences in uptake (Paper III) and additional characterization of uptake 
pathways and intracellular fate could help elucidate the mechanistic impact that changing 
particle physicochemical properties has on different stages of interaction with DCs.  
7.6   Paper IV 
In the literature, there are contradictory results about the influence of membrane rigidity 
(gel or fluid phase) on immunogenicity[108, 125-134] and cellular uptake.[212, 213] 
Theoretical[135-137] and experimental[131, 137] investigations suggest that high particle 
rigidity should be used to optimize cellular uptake; simultaneously, high ligand density has 
also been shown to enhance cellular internalization and impact the cellular uptake 
pathway.[214, 215] In liposomes, these features may be at odds with each other: gel phase 
liposomes are more rigid than fluid phase ones, while a membrane in the fluid phase state 
acts as a 2D liquid, with inherent movement of bound ligands, which may allow for locally 
increased ligand density. It is thus hard to predict the relative importance of rigidity and 
fluidity for liposome-cell membrane interactions and these properties are, additionally, not 
trivial to quantify. In an attempt to address this question, we show in Paper IV an SPR-
based method developed for quantifying surface-induced deformation and binding 
multivalency, and used it to study liposomes of different membrane phase state.  
 
As supported cell membrane mimic, we utilized a silica-supported lipid bilayer with 
varying amounts of cap biotin, to which streptavidin was bound as a model receptor. Gel 
(DSPC) or fluid (DOPC) phase liposomes with a constant ligand (PEG-biotin) density and 
equal size in suspension were subsequently introduced, and the bound mass and film 
thickness of the various layers were simultaneously quantified with multiparametric SPR 
(Figure	  21). Although simplistic, the well-defined nature of this model system allowed for 
precise quantification of the number of bound entities (streptavidin molecules and DSPC- 
or DOPC-based liposomes) and thus the number of receptor-ligands pairs involved in the 
liposome binding. By varying the amounts of cap biotin in the supported lipid bilayer, low 
and high streptavidin coverages were achieved and liposome binding was investigated 
under conditions where the number of available receptors in the cell membrane mimic 
were or were not a limiting factor.  
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Figure 21. A typical dual-wavelength surface plasmon resonance (SPR) measurement with schematics of the 
different steps: (i) injection of 5 wt% glycerol for calibration purposes, (ii) injection of liposomes and 
formation of a supported lipid bilayer with cap biotin, (iii) binding of streptavidin and (iv) binding and 
deformation of DOPC-PEG-biotin or DSPC-PEG-biotin liposomes. 	  
At low streptavidin coverage, where all available streptavidin molecules were recruited in 
liposome binding, each individual fluid and gel phase liposome interacted using 
approximately 80 and 50 streptavidin-biotin pairs, respectively. This was enough to cause 
a decrease in the height of the fluid phase DOPC-PEG-biotin liposomes by approximately 
20 % compared to the gel phase DSPC-PEG-biotin, which appeared to remain 
undeformed. At high streptavidin coverage, the liposome binding was not limited by the 
number of available receptors, but rather by geometrical constraints. In this case, it is not 
possible to precisely know the number of engaged receptor-ligand pairs per liposome, but 
it could be approximated, using the measured streptavidin coverage and liposome film 
thickness, and geometrical considerations (deformation to a truncated sphere shape), that 
at least 110 and 30 streptavidin molecules would fit under the footprint of the fluid and gel 
phase liposomes, respectively. Further, in this regime, DSPC-PEG-biotin deformed less 
than 10 %, while DOPC-PEG-biotin reduced more than 30 % in height. Considering the 
number of available ligands on each liposome (approximately 240 outwards-facing) and 
	  	   79	  
that each streptavidin molecule would reasonably be able to accommodate two PEG-biotin 
ligands, it is likely that almost all of the available ligands on DOPC-PEG-biotin were 
engaged in binding at high streptavidin coverage. For DSPC-PEG-biotin, which utilized a 
much smaller portion of its available ligands in binding, the low mobility of the ligands, 
i.e. the low fluidity of the membrane, appeared to be the limiting factor for deformation. 
 
In summary, we used a well-defined model of liposome-based vaccines and quantified 
binding and deformation upon interaction with a supported cell membrane-mimic using 
multiparametric SPR. Using two different receptor coverages, we were able to quantify 
surface-induced deformation of liposomes in different phase states, and also demonstrated 
that the method can be used to decouple effects related to membrane fluidity and rigidity. 
We are well aware that in the context of vaccine carriers, the streptavidin-biotin model is 
very simplistic; however, an advantage of the supported lipid bilayer-platform is that it can 
easily be customized, and can be transferred to more complex membrane mimics. For 
example, cell membrane-derived supported lipid bilayers[216] could be introduced, 
allowing for studies of liposome deformation in much more biologically relevant scenarios. 
Thus, the method presented in Paper IV and the TIRF-based assay introduced in section 
7.5 could serve as excellent complements to each other in the work towards understanding 
the initial interaction between liposomes and the cell membrane.  
7.7   Paper V 
Paper V focuses on the characterization of extracellular vesicles (EVs) and I contributed to 
this work by guiding the use of self-inserting fluorescent dyes (similar to those used in Paper 
III) to modify EVs for fluorescence microscopy visualization. EVs are a type of natural 
delivery vehicle: a lipid vesicle interspersed with membrane proteins, often carrying both 
nucleic acids and soluble proteins in the aqueous core.[217] They are released by most cell 
types and play an important role in intercellular signalling; in recent years, interest in their 
potential as a drug and vaccine delivery platform has surged.[217-221] However, due to 
their biological origin, one has little control over their composition and physicochemical 
properties. Thus, to be able to fully utilize their potential, or indeed be able to produce 
synthetic substitutes, classification of different subpopulations is critically needed. The vast 
complexity in EV origin, biological function, biomolecular composition and physical 
structure emphasizes the importance of methods capable of single-particle characterization 
with single-nanoparticle resolution. To this end, we utilized surface-sensitive waveguide 
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scattering microscopy, a technique with single vesicle resolution, capable of simultaneous 
scattering and fluorescence detection. The technique is schematically represented in Figure 
22A, and was used for characterization of the correlation between the fluorescence 
emission originating from insertion of the lipophilic dye PKH26 and the (label-free) 
scattering emission of EVs, a parameter that is strongly dependent on EV size (volume). 
The EVs in question, originating from human mast cells, form two distinct subpopulations 
when separated based on buoyant density using a gradient of different concentrations of 
iodixanol and sucrose. The aim was to ascertain whether there were differences in the 
optical properties, especially dye insertion efficiency and the refractive index, of the high-
density (~1.27 g/cm3) and low-density (~1.15 g/cm3) populations. Given that the two 
populations were of comparable size (109 and 97 nm modal diameter for the high- and 
low-density sample, respectively), higher density was expected to correlate with higher 
effective refractive index and, thus, higher scattering intensity. However, the high-density 
population proved to display a factor 3 lower modal scattering intensity (Figure 22B, right 
histogram) compared to the low-density population. Further, the positive correlation 
between fluorescence and scattering intensities within each EV sample suggested an 
increase of incorporated dye molecules with increasing vesicle size, as expected (Figure 
22B, main panel). However, the fluorescence intensities differed between the two EV 
samples, with the high-density sample exhibiting lower fluorescence intensity, despite their 
somewhat larger modal size. This might be due to a higher protein-to-lipid ratio in the 
high-density sample; however, this is unlikely considering that it had lower effective 
refractive index, while proteins have a higher refractive index than lipids. Alternatively, 
the divergence in fluorescence intensity could be due to a difference in labelling efficiency, 
highlighting the importance of understanding the influence that particle properties may 
have on labelling efficiency, as also recently described by Lubart et al.(in review)[67], as 
well as in Paper III. Indeed, the waveguide microscopy technique may be useful to gain 
further understanding, on a single-particle level, of the physicochemical mechanisms 
governing membrane-insertion of lipophilic dyes. 
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Figure 22. (A)  Schematic illustration of the waveguide microscopy setup, utilizing a waveguide chip 
consisting of a silica core encapsulated by a CYTOP cladding layer on both sides, illuminated by the means 
of linearly polarized laser light coupled via an optical fiber.[222] Partial removal of the top cladding layer 
creates a silica sensing surface on which a sample droplet is placed and imaged via a water immersion 
objective. CYTOP and water are closely matched with regards to refractive index (1.34 vs 1.33, respectively), 
allowing for undisrupted propagation of the evanescent wave along the solid-liquid interface.[223] The 
resulting exponentially decaying illumination profile allows for visualization of surface-adsorbed particles 
with high signal-to-noise ratio simultaneously in both scattering and fluorescence mode. (B) Top: PKH26 
fluorescence intensity distribution of high-density (HD) and low-density (LD) EV populations. Right: 
Scattering intensity distribution of HD and LD EV populations. Main: Correlation between the scattering 
and fluorescence intensities for EVs simultaneously visualized in scattering and fluorescence mode (log-log 
plot). 
In summary, Paper V highlights the importance of characterization and classification of 
EVs, and illustrates the benefits of novel techniques, such as the one used therein, for 
characterization of properties that are not commonly reported. Specifically, it can in the 
future help guide the use of self-inserting dyes of the type that was used in Paper III and 
might assist in the further understanding of such results as are presented there.  
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8  	  
Conclusions and outlook 
In this thesis, I set out to further the understanding of how physicochemical properties of 
liposomal vaccine carriers influence the development of protective immunity. When 
working towards this purpose, we identified specific needs for characterization of 
physicochemical properties of the liposomes and explored varying liposome formulations 
in attempts to improve the immunogenicity of fusion proteins based on the mucosal 
adjuvant CTA1-DD. Although we reached some insights during this work, many new 
questions were also raised. In this chapter, some of the questions and opportunities to be 
addressed in the future are presented. The chapter is divided into three parts where, firstly, 
future needs for further characterization of nanoparticle properties are identified. Secondly, 
opportunities for further development of liposome-based vaccine formulations are 
suggested and, lastly, future approaches to vaccine research are discussed. 
8.1   Future opportunities for physicochemical characterization of liposomes 
The general focus of this thesis has been on trying to understand the connection between 
physicochemical properties and liposome immunogenicity; most efforts have been devoted 
to systematic investigations aimed at understanding the influence of membrane phase 
state. This is a complex task as the interplay between liposome rigidity and fluidity is not 
fully understood, which likely contributes to the conflicting results both in our work and 
in the literature (see section 5.5). In this respect, it appears that both particle rigidity, a 
characteristic feature of gel-phase membranes, and high ligand density in the particle-cell 
contact, which can be facilitated by high fluidity (as shown in Paper IV), could be 
beneficial. This may call for specific decoupling of the effects of these two properties in 
order to improve efficacy of vaccine vectors. This is not a facile undertaking, though, as it 
would require, for example, the encapsulation of a rigid core in a lipid bilayer with 
maintained fluidity, but is, on the other hand, likely to yield valuable insights that are 
currently lacking.  
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Another aspect that that could influence the binding avidity and vector deformability is 
related to surface functionalization, antigen coupling in general and the use of flexible 
linkers for protein coupling in particular. This is a point of particular interest, considering 
that the formulations used in Paper I differed mainly with regards to PEGylation and 
number of coupled fusion proteins. Both of these properties could most likely impact the 
way that the liposomes bind to and deform on the cell membrane, although it is difficult to 
predict exactly how. Investigations of such questions place high demands on the 
understanding of how particle composition and functionalization impact the dynamics of 
nanoparticle structure upon interaction with cells. For this, novel analytical techniques and 
model systems for particle characterization are required, and the platform presented in 
Paper IV represents an interesting opportunity to further the understanding of the relations 
between nanoparticle composition, structure and function, especially since the method 
should be compatible with the TIRF-based cellular imaging presented in section 7.5. 
 
In attempting of further the understanding of the connection between physicochemical 
properties of particles and their biological function, we have made use of simplified systems 
for the specific study of individual events or interactions within the immune response. An 
approach common to all our studies, as well as in most others, relies on carrying out an 
initial characterization of the vaccine vectors and assume that their properties remain 
unchanged throughout the biological experiment subsequently performed. It is becoming 
increasingly clear, though, that such an assumption does not necessarily hold. This is 
illustrated, for example, in Paper III, where DSPC-based liposomes were observed to form 
large connected structures upon exposure to cells. Furthermore, it is becoming increasingly 
clear that a protein corona is formed upon nanoparticle exposure to biological fluids.[224] 
This aspect must be considered in future attempts at rationalizing the design of 
nanoparticle-based vaccine formulations and may, in fact, be intentionally taken advantage 
of.[224] As a matter of fact, protein corona-formation could explain the fact that liposomes 
that are seemingly innocuous on their own, appear to have immunostimulatory properties 
even when they are not intentionally used as antigen carriers. For example, liposomes have 
previously been observed in vivo to have an adjuvant effect even when given up to 48 h 
before the antigen.[117] In the context of our research, it is worthwhile to note that, in 
Paper II, DSPC-based liposomes, which are non-immunogenic when administered alone, 
improved antigen presentation and DC activation compared to fusion protein alone, when 
co-administered with the protein. This may suggest that fusion protein might have 
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spontaneously adsorbed to the liposomes independently of intentional covalent coupling. 
These observed and hypothesized changes to the original physicochemical properties of 
liposome formulations upon contact with various biological model systems, emphasize the 
importance of considering and investigating, not only the initial physicochemical profile 
of vaccine vectors, but perhaps even more importantly, how they are changed by 
interaction with various micro-milieus. In the future, investigations into the nature and 
content of the protein corona, as well as potential differences in how coupled protein may 
solubilize from liposome formulations of interest when subjected to complex media, 
should be conducted. 
8.2   Future directions in lipid-based vaccine vector design 
During the work described in this thesis, we found that the non-PEGylated POPC-based 
vaccine vectors perform better than their PEGylated counterparts in vivo (Paper I) and that 
gel phase DSPC-based vectors were superior to fluid phase ones in the in vitro DC model 
system used in Paper II. Although much is left to understand about the mechanisms 
underlying any of the improved functions that we have observed, I here present some 
suggestions for possible future directions in vaccine vector design, with a basis in our 
findings and in the reports of others. 
 
Targeting of vaccine formulations to certain cell types, such as DCs, is a core concept in 
many attempts to create successful mucosal vaccine formulations (see section 5.7), 
including ours. The DD moiety is included in the fusion protein to provide DC targeting 
abilities, and indeed, in Paper III, it was shown that fusion protein was necessary for 
efficient cellular uptake of liposomes. However, it is not known how the DD-portion of 
the fusion proteins employed in this work targets DCs. For this reason, the efficiency and 
specificity of the targeting can likely be improved by replacing the DD-portion with a 
ligand targeting a known receptor. Indeed, the targeting moiety could be chosen to target 
a specific DC subset (see section 2.2) depending on the type of response desired.[225] 
Changes to the fusion protein aside, the advantage of using a liposomal carrier is that other 
components can be incorporated, in addition to vaccine antigens. Lewis X 
oligosaccharides (sugar polymers) have been used to target DCs and as adjuvants[226] and 
it might be interesting to incorporate a lipid-anchored variant in liposome-based vaccine 
formulations. Similarly, TLR-ligands have been used to target DCs (see section 5.7) and it 
has been shown that using a combination of ligands for both cell surface- and endosomal 
	  	   86	  
TLRs induce markedly more effective responses against viral challenge by increasing the 
quality, rather than the quantity, of the Tc cell response.[227] Liposomal carriers are 
excellent candidates for combination with such approaches to modulation of the immune 
response, as they provide opportunity for biomimicry; one may display ligands for cell 
surface TLRs on the exterior of the liposome, while packaging endosomal TLR ligands 
inside. Thus, it would be interesting to use liposome-associated ligands, not only for cell 
targeting, but also for intentional modulation of the immune response in the future 
development of vaccine carrier formulations. 
8.3   Future approaches to vaccine research 
We have, for the most part, taken a reductionist approach to the investigations presented 
in this thesis. The usefulness of such work for furthering the mechanistic understanding of 
biological events as well as the importance of careful characterization of vaccine vectors 
has, I believe, been illustrated. However, while we collect the pieces of the “how 
physicochemical properties of vaccine vectors influence the development of protective 
immunity”-puzzle one by one, it is not trivial to assemble them into a whole, coherent 
picture. Especially in the case of mucosal administration there are many intermediate steps 
(contact with biological fluids, passage through mucosa, intracellular transport, to name a 
few (see chapter 2)) between administration and measurable outcome, with incomplete 
understanding of how earlier steps may influence latter ones, and almost no knowledge 
exists with respect to how they may influence the physicochemical properties of the 
particles. Thus, I believe efforts should be made to generalize and contextualize the 
mechanistic understanding, as has been done in related fields. For example, Miao et al. 
utilized combinatorial lipid libraries to identify promising mRNA delivery vehicles and to 
identify shared common structures among promising lipids.[228] Similarly, Wong et al. 
assembled a library of oil-in-water nanoemulsion-based mucosal adjuvants, which were 
evaluated using a series of high-throughput in vitro assays, attempting to establish 
connections between physicochemical properties, key biological events, and in vivo 
immune responses.[229] Additionally, in later years, systems vaccinology has emerged as 
a promising new field, where systems biology is applied to the challenge of designing and 
evaluating new vaccine candidates.[230] Thus, I believe that, in order for great strides to 
be made in the area of study outlined in this thesis, further mechanistic understanding 
should be combined with, or complemented by, systematic, large-scale screening studies 
and/or systems biology approaches. 
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